Page last updated: 2024-11-04

papaverine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Papaverine is an alkaloid derived from the opium poppy. It has been used medically for over a century, primarily as a smooth muscle relaxant. Papaverine's synthesis involves complex multi-step processes, often starting from thebaine, another opium alkaloid. It acts by inhibiting phosphodiesterase, an enzyme involved in the breakdown of cyclic adenosine monophosphate (cAMP), a key signaling molecule. This leads to increased cAMP levels, which in turn relaxes smooth muscle. Clinically, papaverine is used to treat various conditions, including erectile dysfunction, peripheral vascular disease, and spasms of the digestive tract. Due to its efficacy in relaxing smooth muscle, papaverine is a valuable research tool for studying smooth muscle function and related disorders. Papaverine has been explored for potential applications in treating other conditions, such as cerebral vasospasm and pulmonary hypertension, although its use in these areas remains controversial. Despite its long history, further research into papaverine's mechanisms of action and its therapeutic potential remains ongoing.'

Papaverine: An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

papaverine : A benzylisoquinoline alkaloid that is isoquinoline substituted by methoxy groups at positions 6 and 7 and a 3,4-dimethoxybenzyl group at position 1. It has been isolated from Papaver somniferum. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
PapavergenusA genus of Eurasian herbaceous plants, the poppies (family PAPAVERACEAE of the dicotyledon class Magnoliopsida), that yield OPIUM from the latex of the unripe seed pods.[MeSH]PapaveraceaeThe poppy plant family of the order Papaverales, subclass Magnoliidae, class Magnoliopsida. These have bisexual, regular, cup-shaped flowers with one superior pistil and many stamens; 2 or 3 conspicuous, separate sepals and a number of separate petals. The fruit is a capsule. Leaves are usually deeply cut or divided into leaflets.[MeSH]

Cross-References

ID SourceID
PubMed CID4680
CHEMBL ID19224
CHEBI ID28241
SCHEMBL ID34702
MeSH IDM0015830

Synonyms (140)

Synonym
BRD-K15567136-003-06-6
BRD-K15567136-001-01-1
papaverin
nsc-136630
6,7-dimethoxy-1-veratrylisoquinoline
robaxapap
wln: t66 cnj b1r co1 do1& ho1 io1
nsc136630
papanerine
isoquinoline,7-dimethoxy-1-veratryl-
isoquinoline,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-
s-m-r
isoquinoline, 6,7-dimethoxy-1-veratryl-
1-(3,4-dimethoxy-benzyl)-6,7-dimethoxy-isoquinoline
DIVK1C_000321
KBIO1_000321
NCI60_003183
SDCCGMLS-0003037.P003
1-{[3,4-bis(methyloxy)phenyl]methyl}-6,7-bis(methyloxy)isoquinoline
1-((3,4-dimethoxyphenyl)methyl)-6,7-dimethoxyisoquinoline
papaverine [ban]
einecs 200-397-2
papaverina [italian]
isoquinoline, 1-((3,4-dimethoxyphenyl)methyl)-6,7-dimethoxy-
brn 0312930
cerespan
hsdb 3147
nsc 136630
papanerin
pavacot
6,7-dimethoxy-1-(3,4-dimethoxybenzyl)isoquinoline
isoquinoline, 6,7-dimethoxy-1-veratryl-(8cl)
SPECTRUM_000071
BSPBIO_002153
PRESTWICK3_000583
NCGC00015810-03
cas-61-25-6
lopac-p-3510
tnp00305
NCGC00015810-02
NCGC00015810-01
LOPAC0_000957
BPBIO1_000470
OPREA1_387689
MEGXP0_001880
ACON1_002094
SPECTRUM5_001188
ACON1_000238
PRESTWICK2_000583
IDI1_000321
BSPBIO_000426
4-[(6,7-dimethoxyisoquinolyl)methyl]-1,2-dimethoxybenzene
rs 47
1-[(3,4-dimethoxyphenyl)methyl]6,7-dimethoxyisoquinoline
pavabid
NSC35443 ,
1-(3,4-dimethoxybenzyl)-6,7-dimethoxyisoquinoline
inchi=1/c20h21no4/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16/h5-8,10-12h,9h2,1-4h
ceraspan
1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-isoquinoline
isoquinoline, 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-
AB00053515
58-74-2
papaverine
C06533
DB01113
KBIO2_000471
KBIOSS_000471
KBIO2_005607
KBIOGR_000914
KBIO2_003039
KBIO3_001653
NINDS_000321
SPECTRUM4_000467
SPECTRUM3_000537
SPBIO_002645
PRESTWICK0_000583
PRESTWICK1_000583
SPBIO_001015
SPECTRUM2_000978
OPREA1_810508
NCGC00024428-03
NCGC00015810-04
NCGC00024428-04
chembl19224 ,
bdbm14754
1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline
6,7-dimethoxy-1-veratryl-isoquinoline;hydrochloride
STK039035
NCGC00015810-09
AKOS000277460
EV1 ,
papaverinum
chebi:28241 ,
mesotina (tn)
papaverine (ban)
D07425
BBL012345
CCG-202821
NCGC00015810-07
NCGC00015810-06
NCGC00015810-05
NCGC00015810-08
papaverina
unii-daa13nkg2q
daa13nkg2q ,
5-21-06-00182 (beilstein handbook reference)
NCGC00015810-13
2WEY
noscapine impurity a [ep impurity]
papaverine [vandf]
papaverinum [hpus]
papaverine [mi]
papaverine [mart.]
papaverine [who-dd]
SCHEMBL34702
KS-5336
HMS3561N11
CS-7800
1-(3,4-dimethoxybenzyl)-6,7-dimethoxyisoquinoline #
AB00053515_14
DTXSID4023418 ,
SR-01000003098-10
SBI-0050931.P004
HY-18077
mesotina
Q410374
58-74-2 (free base)
papaverine free base
BRD-K15567136-003-18-1
SDCCGSBI-0050931.P005
NCGC00015810-29
HMS3746M21
NCGC00015810-24
papaverine 100 microg/ml in acetonitrile
EN300-177755
dtxcid603418
noscapine impurity a (ep impurity)
1-((3,4-dimethoxyphenyl)-methyl)-6,7-dimethoxyisoquinoline
papaverine (mart.)

Research Excerpts

Overview

Papaverine (PPV) is a benzylisoquinoline alkaloid from the plant Papaver somniferum (Opium poppy). Papaverine is a vasodilator agent that is an opium alkaloids. Papaverin is a potential anticancer drug in GBM treatment.

ExcerptReferenceRelevance
"Papaverine (PPV) is an alkaloid isolated from the "( In Vitro Effects of Papaverine on Cell Proliferation, Reactive Oxygen Species, and Cell Cycle Progression in Cancer Cells.
Gomes, DA; Joubert, AM; Visagie, MH, 2021
)
2.39
"Papaverine (PPV) is a benzylisoquinoline alkaloid isolated from "( In Vitro Effects of Papaverine on Cell Migration and Vascular Endothelial Growth Factor in Cancer Cell Lines.
Gomes, DA; Joubert, AM; Visagie, MH, 2022
)
2.49
"Papaverine is a potential anticancer drug in GBM treatment."( Anticancer Non-narcotic Opium Alkaloid Papaverine Suppresses Human Glioblastoma Cell Growth.
Akasaki, Y; Ichimura, K; Inada, M; Sato, A; Shindo, M; Tanuma, SI; Yamamoto, Y, 2019
)
2.23
"Papaverine is a topical vasodilator commonly used during microvascular surgery to inhibit undesired vasoconstriction. "( Vasodilation by Verapamil-Nitroglycerin Solution in Microvascular Surgery.
Badran, KW; Benjamin, T; Blackwell, KE; Cedars, E; Heaton, CM; Knott, PD; Plonowska, K; Saggi, S; Seth, R, 2021
)
2.06
"Papaverine is a benzylisoquinoline alkaloid from the plant Papaver somniferum (Opium poppy). "( Repositioning antispasmodic drug Papaverine for the treatment of chronic myeloid leukemia.
Ashok, C; Coumar, MS; Dyavaiah, M; Parcha, PK; Rajasekaran, B; Sarvagalla, S; Sudharshan, SJ, 2021
)
2.35
"Papaverine is a vasodilator agent that is an opium alkaloid. "( Proconvulsant Effect of Papaverine on Penicillin-Induced Epileptiform Activity in Rats.
Cokluk, C; Him, A; Kocacan, SE; Kuruoglu, E; Marangoz, AH; Marangoz, C, 2018
)
2.23
"Papaverine is a useful tool to replace pentoxifylline in ICSI programs to select viable spermatozoa in frozen-thawed sperm samples displaying no or very poor motility."( Papaverine as a replacement for pentoxifylline to select thawed testicular or epididymal spermatozoa before ICSI.
Avon, C; Charles, O; Cortvrindt, R; Giorgetti, C; Hans, E; Lazdunski, P; Salzmann, J; Terriou, P, 2015
)
3.3
"Papaverine is an opium alkaloid, primarily used as an antispasmodic drug and as a cerebral and coronary vasodilator. "( The vasodilator papaverine stimulates L-type Ca(2+) current in rat tail artery myocytes via a PKA-dependent mechanism.
Durante, M; Fusi, F; Manetti, F; Saponara, S; Sgaragli, G, 2016
)
2.22
"Papaverine is a nonspecific inhibitor of phosphodiesterases, leading to increases in both intracellular cGMP and cAMP."( Papaverine Prevents Vasospasm by Regulation of Myosin Light Chain Phosphorylation and Actin Polymerization in Human Saphenous Vein.
Brophy, CM; Cheung-Flynn, J; Hocking, KM; Komalavilas, P; Putumbaka, G; Wise, ES, 2016
)
2.6
"Papaverine hydrochloride is a direct-acting vasodilator used to manage vasospasm during various neurosurgical operations. "( Adverse effects of topical papaverine on auditory nerve function.
Asher, AL; Chadwick, GM; Pollard, RJ; Van Der Veer, CA, 2008
)
2.09
"Papaverine is an effective drug for ameliorating SAH-induced vasospasm."( Magnetic resonance imaging evaluation of subarachnoid hemorrhage in rats and the effects of intracisternal injection of papaverine and nitroglycerine in the management of cerebral vasospasm.
Gupta, D; Jagannathan, NR; Mewar, S; Ramdurg, SR; Sharma, BS; Sharma, U; Suri, A,
)
1.06
"papaverine hydrochloride is a beneficial supplemental therapy to relieve renal colic pain, particularly combined with non-steroidal anti-inflammatory drugs."( Treatment of loin pain suspected to be renal colic with papaverine hydrochloride: a prospective double-blind randomised study.
Asgari, SA; Asli, MM; Aval, HB; Enshaei, A; Esmaeili, S; Farzan, A; Ghanaei, MM; Madani, AH; Maghsoudi, PA; Shakiba, M, 2012
)
1.35
"Papaverine is a vasodilator commonly used in the treatment of vasospasmic diseases such as cerebral spasm associated with subarachnoid hemorrhage, and in the prevention of spasm of coronary artery bypass graft by intraluminal and/or extraluminal administration. "( Papaverine induces apoptosis in vascular endothelial and smooth muscle cells.
Gao, YJ; Lee, RM; Stead, S, 2002
)
3.2
"Papaverine is a non-specific vasodilatory drug, which was found to unexpectedly cause opening of the blood-brain barrier (BBB). "( MMP-9 and EBA immunoreactivity after papaverine mediated opening of the blood-brain barrier.
Bhattacharjee, AK; Ikeda, M; Kohmura, E; Kondoh, T, 2002
)
2.03
"Papaverine is a potent vasodilator of the proximal, intermediate, and distal cerebral arteries and can improve cerebral blood flow (CBF)."( Intra-arterial papaverine infusions for the treatment of cerebral vasospasm induced by aneurysmal subarachnoid hemorrhage.
Couldwell, WT; Liu, JK, 2005
)
1.4
"4. Papaverine is a noncompetitive inhibitor of nucleobase transport in human erythrocytes."( Membrane transport of nucleobases: interaction with inhibitors.
Kraupp, M; Marz, R, 1995
)
0.81
"Papaverine, which is a smooth muscle relaxant, also acted as an antagonist."( A possible approach to the suppression of side effects induced by PGE1.
Kubota, M; Nakabou, Y; Ojima, M; Takada, K, 1995
)
1.01
"Papaverine (PPV) is a nonspecific vasodilator with widespread clinical uses in the treatment of arterial spasm. "( The effects of papaverine on phorbol dibutyrate-induced vasoconstriction in brain slice microvessels.
Jin, Y; Kassell, NF; Lee, KS; Sagher, O; Thai, QA, 1994
)
2.08
"Papaverine was found to be an effective inhibitor of hypoxanthine transport not only in human erythrocytes, but also in the human cell lines HL60 (myeloic) and U937 (monocytic). "( Inhibition of purine nucleobase transport in human erythrocytes and cell lines by papaverine. Investigation of structure-activity relationship.
Kraupp, M; Marz, R; Paskutti, B; Schön, C, 1994
)
1.96
"Papaverine is a nonspecific smooth muscle relaxant and a phosphodiesterase inhibitor. "( Papaverine inhibits transcytotic vesicle transport and lipid excretion into bile in isolated perfused rat liver.
Boyer, JL; Corasanti, J; Hayakawa, T; Hoshino, M; Katagiri, K; Kumai, T; Miyaji, M; Nakai, T; Ohiwa, T; Takeuchi, T, 1992
)
3.17
"Papaverine is a non-specific smooth muscle relaxant and is thought to act at a site beyond the receptor sites on the cell membrane. "( Effects of papaverine on human isolated bladder muscle.
Hertle, L; Nawrath, H, 1990
)
2.11

Effects

Papaverine has been used to prevent graft spasm, but its effect is short-lived. It has been reported to reduce the severity of pruritus associated with atopic dermatitis. Papaverine offers new options for therapy in erectile dysfunction.

ExcerptReferenceRelevance
"Papaverine has been proposed as an alternative heroin biomarker."( Using Papaverine and Its Metabolites, 6-Desmethyl Papaverine and 4',6-Didesmethyl Papaverine as Biomarkers to Improve the Detection Time of Heroin Use.
Goldfine, BL; Korzun, WJ; Nanco, CR; Pierce, KL; Poklis, JL; Wolf, CE, 2019
)
1.72
"Papaverine has been reported to increase the risk of ventricular arrhythmia (VA)."( Evaluation of the risk factors for ventricular arrhythmias secondary to QT prolongation induced by papaverine injection during coronary flow reserve studies using a 4 Fr angio-catheter.
Kaneko, S; Mitamura, Y; Murai, H; Okabe, Y; Otowa, K; Takamura, M; Usui, S, 2018
)
1.42
"Papaverine biosynthesis has remained debatable as two different pathways, NH (involving N-desmethylated intermediates) and the NCH"( 3'O-Methyltransferase, Ps3'OMT, from opium poppy: involvement in papaverine biosynthesis.
Agarwal, P; Dhar, YV; Kumar, RS; Pandey, A; Pathak, S; Shukla, S; Trivedi, PK, 2019
)
1.47
"Papaverine has more cytotoxic effect on MCF-7 CSCs in comparison with parental cells, while CSCs population of MDA-MB-231 is more resistant to papaverine compared with MDA-MB-231 cells."( Cell cycle arrest and apoptogenic properties of opium alkaloids noscapine and papaverine on breast cancer stem cells.
Ghahremani, MH; Kouhsari, SM; Majdzadeh, M; Ostad, SN; Sajadian, S; Vatankhah, M, 2015
)
1.37
"Papaverine has been used to prevent graft spasm, but its effect is short-lived."( Prevention of arterial graft spasm by botulinum toxin: an in-vitro experiment.
Imaizumi, M; Iwata, H; Murakami, E; Takemura, H, 2009
)
1.07
"Papaverine has been used as a pharmacological tool to establish the possible clinical use of PDE10A inhibitors as antipsychotics."( Effects of phosphodiesterase 10 inhibition on striatal cyclic AMP and peripheral physiology in rats.
Ahnaou, A; Drinkenburg, WH; Geys, H; Meert, TF; Straetemans, R; Torremans, A; Van Hemelrijck, A; Vanhoof, G, 2010
)
1.08
"Papaverine has the shortest duration of action."( Comparative efficacies and durations of action of phenoxybenzamine, verapamil/nitroglycerin solution, and papaverine as topical antispasmodics for radial artery coronary bypass grafting.
Black, E; Channon, KM; Dipp, MA; Guzik, TJ; Mussa, S; Taggart, DP, 2003
)
1.25
"Papaverine has potential for producing CBO by multiple routes."( Bronchiolitis obliterans induced by intratracheal papaverine: a novel animal model.
Herndon, B; Molteni, A; Svetlecic, J, 2004
)
1.3
"Papaverine has been used by many surgeons to maximize mammary artery flow perioperatively, but the best delivery method is not known."( Papaverine delivery to the internal mammary artery pedicle effectively treats spasm.
Crawford, FA; Crumbley, AJ; Girard, DS; Kratz, JM; Sutton, JP; Williams, TH; Zellner, JL, 2004
)
2.49
"Papaverine has been used in treating vasospasm following subarachnoid hemorrhage (SAH). "( The effect of papaverine on ion channels in rat basilar smooth muscle cells.
Bai, GY; Han, DH; Kim, CJ; Kwak, YG; Sim, BS; Yang, TK, 2007
)
2.14
"Oral papaverine has been shown to be capable of antagonizing the constipation induced by a single dose of oral morphine. "( Counteracting effect of papaverine on morphine inhibition of gastrointestinal transit in mice.
Palmery, M; Piccolotti, P; Pimpinella, G; Romanelli, L; Tucci, P; Valeri, P, 2008
)
1.17
"Papaverine has offered new options for therapy in erectile dysfunction. "( Fixed drug eruption to papaverine.
Cohen, R; Kirby, KA; Upson, CV, 1994
)
2.04
"Papaverine has the greatest deteriorating effect on PGE1."( Vasoactive cocktails for erectile dysfunction: chemical stability of PGE1, papaverine and phentolamine.
Andrisano, V; Bertaccini, A; Carparelli, F; Cavrini, V; Gotti, R; Martorana, G; Soli, M, 1998
)
1.25
"Papaverine has been reported, largely on the basis of clinical experience, to reduce the severity of pruritus associated with atopic dermatitis. "( Failure of papaverine to reduce pruritus in atopic dermatitis: a double-blind, placebo-controlled cross-over study.
Berth-Jones, J; Graham-Brown, RA, 1990
)
2.11
"The papaverine test has been widely used as a diagnostic procedure in erectile impotence. "( Gravity cavernosometry--a simple diagnostic test for cavernosal incompetence.
Chao, S; Glina, S; Puech-Leao, P; Reichelt, AC, 1990
)
0.84
"The papaverine test has become established in the investigation of impotence. "( Pharmacocavernometry: a modified papaverine test.
Dickinson, IK; Pryor, JP, 1989
)
1.12

Actions

Papaverine is found to inhibit conditioned avoidance responding in rats and mice. It also seems to inhibit PCP- and amphetamine-stimulated locomotor activity in rats. Papaverine did not suppress EDRF production under hypercapnia.

ExcerptReferenceRelevance
"Papaverine may inhibit inflammatory factors and promote the expression of anti-inflammatory factors through the cAMP/PKA and MEK/Erk pathway, thereby inhibiting LPS-induced activation of primary retinal microglia, and the MEK/Erk pathway may be partially regulated by cAMP/PKA, which can provide theoretical basis and experimental basis for its protection of the central nervous system."( Cascade Signals of Papaverine Inhibiting LPS-Induced Retinal Microglial Activation.
Zhou, T; Zhu, Y, 2019
)
1.56
"Papaverine is known to increase cAMP levels in striatum and to decrease blood pressure, body temperature and locomotor activity after systemic administration."( Effects of phosphodiesterase 10 inhibition on striatal cyclic AMP and peripheral physiology in rats.
Ahnaou, A; Drinkenburg, WH; Geys, H; Meert, TF; Straetemans, R; Torremans, A; Van Hemelrijck, A; Vanhoof, G, 2010
)
1.08
"Papaverine-induced increase in p-ERK was localized in striatal neurons receiving D1-enriched presynaptic terminals, as well as in postsynaptic D2-enriched neurons in striatal slices."( The PDE10A inhibitor, papaverine, differentially activates ERK in male and female rat striatal slices.
Baudry, M; Bi, X; Hsu, YT; Liao, G; Oka, T; Tamura, S, 2011
)
1.41
"Papaverine is found to inhibit conditioned avoidance responding in rats and mice and to inhibit PCP- and amphetamine-stimulated locomotor activity in rats."( Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis.
Chambers, L; Chapin, DS; Harms, JF; Lebel, LA; McCarthy, SA; Menniti, FS; Schmidt, CJ; Shrikhande, A; Siuciak, JA; Wong, S, 2006
)
1.06
"Papaverine seems to inhibit the Ba contractions by diverse actions."( [Ba-induced contraction of the guinea pig ileal longitudinal muscle and its inhibition by D-600, benactyzine, and papaverine].
Mukai, T; Takagi, K, 1983
)
1.2
"Papaverine seems to inhibit smooth muscle contractions by diverse actions."( [Histamine-induced contraction of the guinea pig taenia coli and its inhibition by D-600, papaverine, and benactyzine].
Mukai, T; Takagi, K, 1983
)
1.21
"Papaverine did not suppress EDRF production under hypercapnia."( Endothelial modulation of pH-dependent pressor response in isolated perfused rabbit lungs.
Aoki, T; Fujita, H; Miyata, A; Mori, M; Oyamada, Y; Suzuki, K; Suzuki, Y; Takasugi, T; Yamaguchi, K, 1996
)
1.02
"Papaverine did not increase both cAMP and cGMP contents in the uterus in the presence of H-65K+ or oxytocin."( Mechanism of relaxant response to papaverine on the smooth muscle of non-pregnant rat uterus.
Gotoh, K; Nakajyo, S; Orita, S; Shimizu, K; Takahashi, M; Urakawa, N; Yoshihara, E, 2000
)
1.31
"Papaverine did not increase transcapillary movement of protein, Histamine (5 microgram/kg/min) was added to the blood and 10 to 15 min later the dose level was increased to 60 microgram/kg/min."( Nonhemodynamic effects of histamine on gracilis muscle capillary permeability.
Baker, CH, 1979
)
0.98
"A papaverine-induced flow increase (15 mg."( Operative flow measurements and coronary bypass graft patency.
Barner, HB; Codd, JE; Kaiser, GC; Marco, JD; Mudd, JG; Willman, V, 1976
)
0.81
"Papaverine which did not cause a significant elevation of pH also definitely increased bacterial counts and nitrite concentration of gastric juice."( [Bacterial colonization of the stomach caused by acid neutralization and inhibition of stomach emptying].
Domschke, W; Greim, G; Hagel, HJ; Mueller, RL; Ruppin, H; Schoenherr, U, 1985
)
0.99

Treatment

Papaverine treatment improved spatial and object recognition memories in R6/1 mice. Papaverine pre-treatment led to increased phosphorylation of the heat shock-related protein 20 (HSPB6)

ExcerptReferenceRelevance
"Papaverine treatment also led to a dose-dependent downregulation of PI3K and phospho-Akt expression."( Papaverine selectively inhibits human prostate cancer cell (PC-3) growth by inducing mitochondrial mediated apoptosis, cell cycle arrest and downregulation of NF-κB/PI3K/Akt signalling pathway.
Huang, H; Li, LJ; Wei, AY; Zhang, HB,
)
2.3
"Papaverine treatment improved spatial and object recognition memories in R6/1 mice, and significantly increased pGluA1 and pCREB levels in R6/1 mice hippocampus."( PDE10 inhibition increases GluA1 and CREB phosphorylation and improves spatial and recognition memories in a Huntington's disease mouse model.
Alberch, J; Arumí, H; Carretón, O; Giralt, A; Pérez-Navarro, E; Saavedra, A; Tyebji, S, 2013
)
1.11
"Papaverine pre-treatment also led to increased phosphorylation of the heat shock-related protein 20 (HSPB6) and the vasodilator stimulated phosphoprotein (VASP), as well as decreased filamentous actin (F-actin) levels suggesting depolymerization of actin."( Papaverine Prevents Vasospasm by Regulation of Myosin Light Chain Phosphorylation and Actin Polymerization in Human Saphenous Vein.
Brophy, CM; Cheung-Flynn, J; Hocking, KM; Komalavilas, P; Putumbaka, G; Wise, ES, 2016
)
2.6
"Papaverine treatment (1 x 10(-7) - 5 x 10(-7) - 1 x 10(-6) M) before or after the opioid agonists was able of both preventing and reversing the naloxone-induced contracture after exposure to mu (morphine and DAGO) or k (U50-488H) opiate agonists in a concentration-dependent fascion."( The effect of papaverine on acute opiate withdrawal in guinea pig ileum.
Capasso, A; Loizzo, A, 2003
)
1.4
"Papaverine-treatment increased trypan blue staining of cultured human coronary artery endothelial cells regardless of papaverine diluent (normal saline of pH 4.5 or 7.4 or blood)."( Arterial endothelial denudation by intraluminal use of papaverine-NaCl solution in coronary bypass surgery.
Hess, MW; Kovanen, PT; Mäyränpää, M; Simpanen, J; Werkkala, K, 2004
)
1.29
"Papaverine treatment caused a pronounced increase in GST activity and GSH content at the higher dosing level in the rat liver and lung."( Papaverine, an opium alkaloid influences hepatic and pulmonary glutathione S-transferase activity and glutathione content in rats.
Aneja, R; Chandra, R; Dass, SK; Sharma, A; Talwar, A,
)
2.3
"Papaverine treatment, to prevent vascular-GFR changes without blocking alpha-receptors, resulted in similar renin responses."( Neural and vascular interaction in renin response to graded renal nerve stimulation.
Ammons, WS; Koyama, S; Manning, JW, 1982
)
0.99
"Papaverine-treated veins which were subjected to brief periods of distension at pressures of 100 mmHg or greater demonstrated large gaps between the endothelial lining cells."( Vein contraction and smooth muscle cell extensions as causes of endothelial damage during graft preparation.
Baumann, FG; Catinella, FP; Cunningham, JN; Spencer, FC, 1981
)
0.98
"In papaverine-treated rabbits, all arterioles dilated and a larger increase in perivascular interstitial thickness was observed."( Pulmonary microvascular and perivascular interstitial geometry during development of mild hydraulic edema.
Bettinelli, D; Boschetti, F; Candiani, A; Crisafulli, B; Del Fabbro, M; Miserocchi, G; Negrini, D, 2001
)
0.82
"Papaverine treatment, when started one day prior to tumor inoculation or 10 days after tumor implant, resulted in complete prevention of all detectable metastatic growth, while having no apparent effect on local tumor growth."( A study of the effect of papaverine in neuroblastoma using the experimental C1300 murine system.
Murphy, GP; Wajsman, Z; Williams, P, 1978
)
1.28
"Papaverine treatment can solve more than 70% of male impotence cases, so that the real clue to the diagnosis of impotence is to discriminate between patients who can be treated by papaverine alone and patients deserving thorough investigation."( Diagnosis of male impotence after intracavernous papaverine test.
De Rose, AF; Giuliani, L; Pittaluga, P; Puppo, P, 1988
)
1.25
"papaverine) for the treatment of erectile dysfunction."( Prolonged erections following intracorporeal injection of medications to overcome impotence.
Carati, CJ; Earle, CM; Keogh, EJ; Lord, DJ; Tulloch, AG; Watters, GR; Wisniewski, ZS, 1988
)
1
"Pre-treatment with papaverine completely inhibited norepinephrine-induced force generation, blocked increases in [Ca2+]i and led to a decrease in the phosphorylation of myosin light chain."( Papaverine Prevents Vasospasm by Regulation of Myosin Light Chain Phosphorylation and Actin Polymerization in Human Saphenous Vein.
Brophy, CM; Cheung-Flynn, J; Hocking, KM; Komalavilas, P; Putumbaka, G; Wise, ES, 2016
)
2.2
"Treatment with papaverine solution markedly increased the endothelial denudation (grades from 6.2+/-1.7 to 10.0+/-3.5; mean+/-SD; P=0.004). "( Arterial endothelial denudation by intraluminal use of papaverine-NaCl solution in coronary bypass surgery.
Hess, MW; Kovanen, PT; Mäyränpää, M; Simpanen, J; Werkkala, K, 2004
)
0.92
"Treatment with papaverine induced an equal inhibition on the phasic and tonic components of Ba contractions and the Ba contraction in the Ca-free solution."( [Ba-induced contraction of the guinea pig ileal longitudinal muscle and its inhibition by D-600, benactyzine, and papaverine].
Mukai, T; Takagi, K, 1983
)
0.82
"Treatment with papaverine injections is generally inexpensive and effective to overcome the multifactorial causes of erectile dysfunction in this population."( Aetiopathogenesis and management of impotence in diabetic males: four years experience from a combined clinic.
Boulton, AJ; Chen, TF; Payne, S; Veves, A; Webster, L, 1995
)
0.63
"A pretreatment with papaverine (10(-5) approximately 10(-4) M) dose-dependently reduced the magnitude of the phenylephrine (10(-6) M)-induced contracture, more prominently in the tonic than in the phasic component, while reduced that of the high K+ (30 mM)-induced contracture in both components."( [Mechanisms of relaxing action of papaverine on isolated canine corpus cavernosum].
Yoshida, K, 1993
)
0.88
"Treatment with papaverine prior to and during the 60-minute histamine suffusion failed to prevent the mediator-stimulated vascular leakage response."( Evidence that prolonged histamine suffusions produce transient increases in vascular permeability subsequent to the formation of venular macromolecular leakage sites. Proof of the Majno-Palade hypothesis.
Adamski, SW; Ayele, W; Grega, GJ; Horan, KL; Langone, JJ, 1986
)
0.61

Toxicity

Papaverine and MPP+ were most toxic to TH-positive neurons among the compounds tested. Papaverine inhibited RSV replication in vitro but the median minimal toxic dose-median minimal inhibitory concentration ratios (MTD50:MIC50) in vitro and in vivo for papaverine were less than 4. LD50 and ileum ED50.

ExcerptReferenceRelevance
" LD50 and ileum ED50, was greater than the therapeutic index of papaverine."( [Action on the isolated guinea-pig ileum and toxicity of some derivatives of 1,5-bis-(3,4-methylendioxyphenyl)-n. pentane].
Agozzino, S; Di Carlo, R; Reboani, C, 1975
)
0.49
" To determine whether other clinical or procedural factors predispose patients to this side effect of papaverine, these 5 patients were compared with 25 control patients who were matched for gender and extent of coronary artery disease."( Polymorphous ventricular tachycardia: a side effect of intracoronary papaverine.
Kienzle, MG; Marcus, ML; Rossen, JD; Simonetti, I; Talman, CL; Winniford, MD, 1990
)
0.73
"The present study was undertaken to assess and compare the toxic effects of papaverine hydrochloride and its metabolites."( Toxicity assessment of papaverine hydrochloride and papaverine-derived metabolites in primary cultures of rat hepatocytes.
Acosta, D; Davila, JC; Davis, PJ; Reddy, CG, 1990
)
0.82
" However, for the safe implementation of this method, close and intensive cooperation between the physician and his patient is a condition that has to be guaranteed."( How safe is the treatment of impotence with intracavernous autoinjection?
Ludwig, G; Zentgraf, M; Ziegler, M, 1989
)
0.28
" Our results demonstrate that iodide in excess, after being oxidized or organified, is directly toxic for iodine-deficient thyroid cells."( Direct toxic effect of iodide in excess on iodine-deficient thyroid glands: epithelial necrosis and inflammation associated with lipofuscin accumulation.
Colin, I; Denef, JF; Mahmoud, I; Many, MC, 1986
)
0.27
"6 x 10(10) cells daily during 7 d no adverse reactions were observed."( Acute toxicity testing of some herbicides-, alkaloids-, and antibiotics-metabolizing soil bacteria in the rat.
Classen, HG; Eberspächer, J; Kaiser, A; Lingens, F, 1981
)
0.26
" We conclude that self-injection with a combination of papaverine and phentolamine is an efficient and safe long-term treatment for erectile dysfunction."( [Effectiveness and safety of cavernous body auto-injection therapy with papaverine/phentolamine. Study group].
Hartmann, U; Thon, WF, 1993
)
0.77
"The adverse effects of vacuum therapy and intracavernous self-injection in patients on warfarin do not exceed the rate in the general urological population."( Minimally invasive therapies in the treatment of erectile dysfunction in anticoagulated cases: a study of satisfaction and safety.
Donatucci, CF; Henderson, D; Limoge, JP; Olins, E, 1996
)
0.29
" Papaverine and MPP+ were most toxic to TH-positive neurons among the compounds tested."( Neurotoxic effects of papaverine, tetrahydropapaverine and dimethoxyphenylethylamine on dopaminergic neurons in ventral mesencephalic-striatal co-culture.
Goto, K; Hattori, T; Mizuno, Y; Mochizuki, H; Nakamura, N, 1997
)
1.52
" The combination of papaverine with either PGE(1) or phentolamine had a cumulative toxic effect, and maximal toxicity (70%) was observed with the triple combination."( Vasoactive agents induce cytotoxicity in cultured human penile smooth muscle cells.
Monga, M; Pagnon, V; Rajasekaran, M, 2002
)
0.64
" Studies have shown that sildenafil may not be effective in all patients, and has been associated with a variety of adverse effects and an adverse interaction with nitrates and inhibitors of cytochrome P450 enzymes."( Combination therapy for erectile dysfunction: a randomized, double blind, unblinded active-controlled, cross-over study of the pharmacodynamics and safety of combined oral formulations of apomorphine hydrochloride, phentolamine mesylate and papaverine hyd
Castaneda, J; Castell, R; Hurley, D; Lammers, PI; Lipezker, M; Loehr, LA; Lowrey, F; Ponce de Leon, R; Rubio-Aurioles, E, 2002
)
0.5
" Authors collected the safety data from clinical studies between 1964-1998 for the determination of the adverse event frequency."( [Safety profile of NO-SPA].
Singer, J; Tar, A, 2002
)
0.31
" This effect is consistent with a permanent toxic effect to human brain."( Neurotoxicity of intra-arterial papaverine preserved with chlorobutanol used for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage.
DeArmond, SJ; Dillon, WP; Dowd, CF; Halbach, VV; Higashida, RT; Johnston, SC; Ko, NU; Lawton, MT; Setty, D; Smith, WS; Young, WL, 2004
)
0.61
" This study supports previous reports and provides neurophysiological evidence of an adverse effect on the auditory nerve."( Adverse effects of topical papaverine on auditory nerve function.
Asher, AL; Chadwick, GM; Pollard, RJ; Van Der Veer, CA, 2008
)
0.64
" The average temporal delay between papaverine and the onset of an adverse BAEP change was 5 min."( Adverse effects of topical papaverine on auditory nerve function.
Asher, AL; Chadwick, GM; Pollard, RJ; Van Der Veer, CA, 2008
)
0.92
" The complete disappearance of BAEP waveforms with a consistent temporal delay suggests a possible adverse effect on the proximal eighth nerve."( Adverse effects of topical papaverine on auditory nerve function.
Asher, AL; Chadwick, GM; Pollard, RJ; Van Der Veer, CA, 2008
)
0.64
" The need for rescue medication and the presence of adverse effects were considered as secondary outcome of the study."( Intramuscular drotaverine and diclofenac in acute renal colic: a comparative study of analgesic efficacy and safety.
Akantappa Bandakkanavar, TK; Arora, P; Dash, A; Maiti, R, 2012
)
0.38
" Secondary: Number of school days missed during the study period, parental satisfaction (on a Likert scale), and occurrence of solicited adverse effects."( Efficacy and Safety of Drotaverine Hydrochloride in Children with Recurrent Abdominal Pain: A Randomized Placebo Controlled Trial.
Akhtar, H; Narang, M; Shah, D, 2015
)
0.42
" Frequency of adverse events during follow-up period was comparable between children receiving drotaverine or placebo (46."( Efficacy and Safety of Drotaverine Hydrochloride in Children with Recurrent Abdominal Pain: A Randomized Placebo Controlled Trial.
Akhtar, H; Narang, M; Shah, D, 2015
)
0.42
"Drotaverine hydrochloride is an effective and safe pharmaceutical agent in the management of recurrent abdominal pain in children."( Efficacy and Safety of Drotaverine Hydrochloride in Children with Recurrent Abdominal Pain: A Randomized Placebo Controlled Trial.
Akhtar, H; Narang, M; Shah, D, 2015
)
0.42
"We critically reviewed current literature on the adverse effects of iPPV in aneurysmal surgery with a focus on oculomotor nerve involvement."( Prolonged Intracisternal Papaverine Toxicity: Index Case Description and Proposed Mechanism of Action.
Alambyan, V; Kohen, M; Manjila, S; Ostergard, T; Pace, J; Ramos-Estebanez, C; Zhou, X, 2018
)
0.78
" The secondary outcomes were measured by the Bristol scale, and the 36-item short form health survey (SF-36), as well as the adverse events recorded during the treatment period."( Randomized controlled study of efficacy and safety of drotaverine hydrochloride in patients with irritable bowel syndrome.
Qi, XX; Wan, XY; Xue, XC, 2017
)
0.46
" Additionally, no serious and significant differences in adverse events were found in and between both groups."( Randomized controlled study of efficacy and safety of drotaverine hydrochloride in patients with irritable bowel syndrome.
Qi, XX; Wan, XY; Xue, XC, 2017
)
0.46
" This was performed by comparison of mean pain intensity difference, total pain relief at 2 h, onset of pain relief, decrease in number of pain episodes, global improvement, and adverse effects."( Efficacy and safety of fixed-dose combination of drotaverine hydrochloride (80 mg) and paracetamol (500 mg) in amelioration of abdominal pain in acute infectious gastroenteritis: A randomized controlled trial.
Koli, J; Narang, S, 2018
)
0.48
"Fixed-dose combination of drotaverine hydrochloride (80 mg) and PCM (500 mg) is an effective and safe antispasmodic agent in abdominal pain associated with acute infectious gastroenteritis."( Efficacy and safety of fixed-dose combination of drotaverine hydrochloride (80 mg) and paracetamol (500 mg) in amelioration of abdominal pain in acute infectious gastroenteritis: A randomized controlled trial.
Koli, J; Narang, S, 2018
)
0.48

Pharmacokinetics

Papaverine plasma level data in man reported in the literature. Administration of papaverine did not change the AUC and Cmax, but tmax was significantly longer.

ExcerptReferenceRelevance
" The administration of papaverine did not change the AUC and Cmax, but tmax was significantly longer."( Effect of papaverine and atropine on pharmacokinetics of paracetamol administered orally.
Gawrońska-Szklarz, B; Kaźmierczyk, J; Samochowiec, L; Wójcicki, J,
)
0.84
" Toxicological and pharmacodynamic studies were done in the cardiovascular system and in vitro on certain muscles."( [Experimental toxicological and pharmacodynamic studies of a triple drug association (adrenaline, atropine and papaverine) with anti-bronchospastic activity].
Alise, G; Del Vecchio, F; Di Tonto, B; Giordano, L; Lampa, E; Rosatti, F; Rossi, F; Vacca, C,
)
0.34
"A retrospective pharmacokinetic analysis was done of papaverine plasma level data in man reported in the literature."( Pharmacokinetics of papaverine in man.
Hammer, GV; Ritschel, WA, 1977
)
0.83
" Based on a one-compartment model, the time of invasion, the half-life of elimination, the volume of distribution and the absorption rate of papaverine were calcualted."( [The pharmacokinetics of papaverine and its bioavailability from a sustained-action preparation].
Fleissig, W; Götz, R; Haase, W; Juhran, VW, 1975
)
0.76
" The pharmacokinetic parameters were determined using either curve-fitting (RE-SID) or compartment model independent method (AUC-RPP)."( Pharmacokinetics and bioavailability of papaverine HCl after intravenous, intracorporeal and penis topical administration in beagle dogs.
Bauman, DH; Kraus, C; Ritschel, WA; Shaaya, AN, 1992
)
0.55
" The pharmacokinetic parameters were first determined using a curve fitting program (RESID), and then evaluated by SAS statistics."( Pharmacokinetics of papaverine HCl upon intravenous route of administration in old and young beagle dogs.
Kraus, C; Ritschel, WA; Sakr, A; Shaaya, A,
)
0.45
"This in vivo study was designed to obtain bioavailability data and a definite pharmacokinetic profile of papaverine HCl in Beagle dogs following intravenous (IV), peroral (PO), rectal, vaginal, topical, and buccal administration of different papaverine HCl formulations."( Pharmacokinetics and bioavailability of papaverine HCl following intravenous, peroral, rectal, vaginal, topical and buccal administration in beagle dogs.
Hutchings, D; Kraus, C; Menon, A; Ritschel, WA; Sakr, A; Shaaya, A; Ulmer, J, 1991
)
0.76
" The short duration of the bypass procedure and the continuous changes during the process hamper a rigorous pharmacokinetic evaluation."( Cardiopulmonary bypass and the pharmacokinetics of drugs. An update.
Bogaert, MG; Buylaert, WA; Herregods, LL; Mortier, EP, 1989
)
0.28
" The structural identifiability of the model was proved by computer analysis, and the pharmacokinetic parameters were determined."( The fate of drotaverine-acephyllinate in rat and man. II. Human pharmacokinetics of drotaverine-14C-acephyllinate.
Deutsch, T; Eckhardt, S; Kerpel-Fronius, S; Szatmári, I; Szüts, T; Vargay, Z; Várkonyi, P,
)
0.13
" The pharmacokinetic parameters, such as elimination half-life, plasma clearance, renal clearance and apparent volume of distribution, were not influenced by the route of drug administration."( Pharmacokinetics and bioavailability of drotaverine in humans.
Bolaji, OO; Ogunbona, FA; Ogundaini, AO; Olugbade, TA; Onyeji, CO,
)
0.13
"Allometric scaling is an empirical examination of the relationships between the pharmacokinetic parameters and size (usually body weight, ratio of organ- and body weight, breathing number, etc."( [Interspecies allometric scaling in pharmacokinetics of drugs].
Sylvia, M, 1998
)
0.3
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" The here obtained pharmacodynamic profiles of the drugs suggest that both milrinone and theophylline may be considered as potent relaxing agents of the lower oesophageal sphincter."( Milrinone and theophylline act as lower oesophageal sphincter relaxing agents: a comparative pharmacodynamic study in the rabbit.
Batzias, GC; Koutsoviti-Papadopoulou, M; Psarra, TA, 2009
)
0.35
"Non-compartmental pharmacokinetic analysis of diclofenac sodium (DIC) and papaverine hydrochloride (PAP) after oral administration of composed tablets to rabbits was developed."( PHARMACOKINETICS OF DICLOFENAC SODIUM AND PAPAVERINE HYDROCHLORIDE AFTER ORAL ADMINISTRATION OF TABLETS TO RABBITS.
Jawień, W; Kasperek, R; Poleszak, E; Zimmer, Ł,
)
0.63

Compound-Compound Interactions

Papaverine and PGE2 can synergistically induce neuronal differentiation as well as decrease the malignancy of human prostatic cancer LNCaP cells.

ExcerptReferenceRelevance
"We performed a double-blind, crossover study using objective measurements to compare maximum rigidity and duration of erections with papaverine hydrochloride in combination with phentolamine mesylate and/or prostaglandin E1."( Objective double-blind evaluation of erectile function with intracorporeal papaverine in combination with phentolamine and/or prostaglandin E1.
Allen, RP; Brendler, CB; Engel, RM; Smolev, JK, 1992
)
0.72
" This vasoactive drug combination has been used in 116 patients for diagnostic testing and subsequent treatment."( An improved vasoactive drug combination for a pharmacological erection program.
Barada, JH; Bennett, AH; Carpenter, AJ, 1991
)
0.28
" prostaglandin E1 in combination with papaverine (although the difference is not statistically significant)."( Intracavernous injection of prostaglandin E1 in combination with papaverine: enhanced effectiveness in comparison with papaverine plus phentolamine and prostaglandin E1 alone.
Floth, A; Schramek, P, 1991
)
0.79
" While intracavernosal VIP alone produced disappointing penile responses, its combination with papaverine potentiated the response to this drug, probably by increasing venous outflow resistance."( Penile response to intracavernosal vasoactive intestinal polypeptide alone and in combination with other vasoactive agents.
Bloom, SR; Kiely, EA; Williams, G, 1989
)
0.5
" Two cases with either stage III or IV neuroblastoma, whose tumors had not been extirpated at the initial operation, were treated by intra-aortic PGE1 infusion combined with oral papaverine and conventional anti-malignant chemotherapy."( [Intra-aortic PGE1 infusion combined with anti-malignant chemotherapy in the treatment of advanced neuroblastoma].
Hayakawa, K; Inoue, S; Munakata, H; Nara, K; Ono, K; Sato, S; Takahashi, K, 1985
)
0.46
" Patients were treated with sildenafil citrate alone or in combination with intracavernosal injection therapy."( Treatment of intracorporeal injection nonresponse with sildenafil alone or in combination with triple agent intracorporeal injection therapy.
Johnson, H; McMahon, CG; Samali, R, 1999
)
0.3
" Sildenafil in combination with intracavernosal injection is associated with a 33% incidence of adverse effects, including a 20% incidence of dizziness."( Treatment of intracorporeal injection nonresponse with sildenafil alone or in combination with triple agent intracorporeal injection therapy.
Johnson, H; McMahon, CG; Samali, R, 1999
)
0.3
" These results suggest that papaverine combined with PGE2 can synergistically induce neuronal differentiation as well as decrease the malignancy of human prostatic cancer LNCaP cells."( Papaverine combined with prostaglandin E2 synergistically induces neuron-like morphological changes and decrease of malignancy in human prostatic cancer LNCaP cells.
Matsushima, H; Ohta, Y; Ozawa, H; Shimizu, T; Takeda, K,
)
1.87

Bioavailability

Papaverine hydrochloride loaded gels, films and electrospun fibers were prepared for buccal drug delivery. The absolute bioavailability of papaverine HCl was determined to be 102. The optimal vehicle is suggested for the formulation of suppositories containing Papaverine Hydrochloride.

ExcerptReferenceRelevance
"The bioavailability of papaverine, administered as sustained release capsules, an elixir, and soft gelatin capsules, was studied with volunteers."( Papaverine hydrochloride: the evaluation of two new dosage forms.
Arnold, JD; Baldridge, J; Brody, G; Riley, B, 1977
)
2.01
"The bioavailability of sustained-release papaverine HCl dosage forms were compared to equivalent doses of the drug administered as an elixir and conventional compressed tablets to 12 healthy human subjects."( The influence of dosage form on papaverine bioavailability.
Gollamudi, R; Meyer, MC; Straughn, AB,
)
0.68
" An increase of the extent of bioavailability of paracetamol was observed after the atropine administration, however the absorption of the drug was delayed."( Effect of papaverine and atropine on pharmacokinetics of paracetamol administered orally.
Gawrońska-Szklarz, B; Kaźmierczyk, J; Samochowiec, L; Wójcicki, J,
)
0.53
" The suitability of this procedure for plasma sample analysis from a bioavailability study was demonstrated."( Simple and rapid high-pressure liquid chromatographic determination of papaverine in plasma.
Hanigan, JJ; McClurg, JE; Pierson, SL; Taylor, RE, 1979
)
0.49
" The new preparation shows bioavailability equivalent to a normal papaverine but substantially more prolonged papaverine blood levels."( Papaverine blood levels after administration of a sustained-release preparation. Short communication.
Cerchiari, D; Coppi, G; Maggi, GC, 1977
)
1.94
" CV-705 was well absorbed through the digestive tract."( [Vasodilator action of (+/-)-1-(3, 4, 5-trimethoxybenzyl)-6-hydroxy-1, 2, 3, 4-tetrahydroisoquinoline hydrochloride (CV-705) in anesthetized dogs (author's transl)].
Ikezawa, K; Kiyomoto, A; Nagao, T; Nakajima, H; Sato, M, 1977
)
0.26
" HCl; No-SpaR] is well absorbed after subcutaneous and oral administration in mice."( Absorption, distribution and elimination of drotaverine.
Knoll, J; Lengyel, M; Magyar, K, 1978
)
0.26
" Thus, YC-93 is a potent bu low-toxic vasodilator agent acting preferentially and perhaps directly on cerebral and coronary vascular beds and is well absorbed from gastrointestinal tract into blood stream."( Vasodilator profile of a new 1,4-dihydropyridine derivative, 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-[2-(N-benzyl-N-methylamino)]-ethyl ester 5-methyl ester hydrochloride (YC-93).
Maeno, H; Nomura, T; Sado, T; Takenaka, T; Usuda, S, 1976
)
0.26
" It was developed for use in bioavailability studies of therapeutic doses of codeine sulfate."( Gas-chromatographic measurement of codeine and norcodeine in human plasma.
Brunson, MK; Nash, JF, 1975
)
0.25
" The bioavailability of the drug was assessed in the same animals following single administration of the sustained-action preparation Panergon (papaverine-hydrochloride)."( [The pharmacokinetics of papaverine and its bioavailability from a sustained-action preparation].
Fleissig, W; Götz, R; Haase, W; Juhran, VW, 1975
)
0.76
" The absolute bioavailability of papaverine HCl was determined to be 102."( Pharmacokinetics and bioavailability of papaverine HCl after intravenous, intracorporeal and penis topical administration in beagle dogs.
Bauman, DH; Kraus, C; Ritschel, WA; Shaaya, AN, 1992
)
0.83
" Finally, with the help of linear regression calculation and in view of the in vitro relative bioavailability values the optimal vehicle is suggested for the formulation of suppositories containing Papaverine hydrochloride."( [Formulation and analysis of suppositories containing papaverine hydrochloride. Part 2. In vitro membrane diffusion studies].
Regdon, G; Selmeczi, B; Vastag, T, 1991
)
0.72
"This in vivo study was designed to obtain bioavailability data and a definite pharmacokinetic profile of papaverine HCl in Beagle dogs following intravenous (IV), peroral (PO), rectal, vaginal, topical, and buccal administration of different papaverine HCl formulations."( Pharmacokinetics and bioavailability of papaverine HCl following intravenous, peroral, rectal, vaginal, topical and buccal administration in beagle dogs.
Hutchings, D; Kraus, C; Menon, A; Ritschel, WA; Sakr, A; Shaaya, A; Ulmer, J, 1991
)
0.76
"The mechanism of transport of desciclovir (DCV)--a structural analogue and prodrug of acyclovir (ACV) which provides an improved oral bioavailability of ACV--was investigated in human erythrocytes with a "papaverine-stop" assay."( Desciclovir permeation of the human erythrocyte membrane by nonfacilitated diffusion.
Domin, BA; Mahony, WB; Zimmerman, TP, 1991
)
0.47
" The bioavailability of the drug was highly variable with a mean of 28% (range 5-99%) but reproducible within the same individual (4 of the volunteers) after a repeated (80 mg) oral dose."( Variable bioavailability of papaverine.
Berg, G; Hammar, M; Jönsson, KA; Norlander, B, 1988
)
0.57
"Investigations have proved that in the case of po preparations disintegration time, dissolution rate and in vivo absorption rate are closely interrelated."( Correlation between disintegration, dissolution and in vivo absorption rate in the case of compounds with benzyl-isoquinoline structures and its pharmacokinetic aspects.
Marton, S; Rácz, I; Szentmiklósi, P,
)
0.13
" The products had been the subject of earlier in vivo bioavailability studies with human subjects."( In vivo-in vitro correlations with a commercial dissolution simulator II: papaverine, phenytoin, and sulfisoxazole.
Meyer, MC; Yau, MK, 1983
)
0.5
" Furthermore, KB-944 is well absorbed from the intestinal tract, and produces a long-acting increase in the coronary blood flow."( Vasodilator action of KB-944, a new calcium antagonist.
Ito, K; Kanazawa, T; Morita, T; Nose, T; Yoshino, K, 1982
)
0.26
"The bioavailability of non "normal-acting" and three "delayed" papaverine formulations was compared in twenty hospitalized human subjects."( Papaverine bioavailability in delayed absorption formulations.
Melloni, GF; Melloni, R, 1981
)
1.94
"The pharmacokinetics and bioavailability of drotaverine was studied in 10 healthy volunteers after administration of single 80 mg oral and intravenous doses of the HCl salt of the drug, in a crossover fashion."( Pharmacokinetics and bioavailability of drotaverine in humans.
Bolaji, OO; Ogunbona, FA; Ogundaini, AO; Olugbade, TA; Onyeji, CO,
)
0.13
"The effect of carriers--potato starch, sodium carboxymethyl cellulose, sodium alginate, and hydrophilic agents--polyethyleneglycol 1500 (PEG 1500), PEG 4000, glyceryl monostearate (MSG), Tween 65, on bioavailability of papaverine from spheres were studied on rabbits."( Effect of carriers and hydrophilic agents on papaverine spheres bioavailability.
Czarnecki, W; Wielgus, S,
)
0.58
", the sum of NO(2)- and NO(3)-, is frequently used to assess NO bioavailability in vivo."( Plasma nitrite rather than nitrate reflects regional endothelial nitric oxide synthase activity but lacks intrinsic vasodilator action.
Deussen, A; Feelisch, M; Kelm, M; Lauer, T; Preik, M; Rassaf, T; Strauer, BE, 2001
)
0.31
" This study set out to test the hypothesis that in vivo gene transfer of GTPCH I to endothelial cells could increase bioavailability of BH4, enhance biosynthesis of nitric oxide and thereby enhance endothelium-dependent relaxations mediated by nitric oxide."( In vivo expression and function of recombinant GTPCH I in the rabbit carotid artery.
Hynes, SO; Katusic, ZS; Kovesdi, I; O'Brien, T; Richardson, DM; Smith, LA, 2004
)
0.32
"The bioavailability of drotaverine (CAS 14009-24-6) was investigated after oral administration of a drotaverine capsule preparation (20 mg Droxa mite) and compared to that of a reference tablet preparation."( Bioavailability study of drotaverine from capsule and tablet preparations in healthy volunteers.
Balcerkiewicz, M; Drobnik, L; Dubai, V; Dyderski, S; Grześkowiak, E; Szałek, E, 2004
)
0.32
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
" Faster drug transports and higher bioavailability were also observed in rabbits."( Systemic enhancement of papaverine transdermal gel for erectile dysfunction.
El-Kamel, AH; Khalil, SA; Wen, MM, 2012
)
0.69
" The reason for these differing results is unclear, but may be related to the low bioavailability after oral administration."( Effects of orally administered moxaverine on ocular blood flow in healthy subjects.
Boltz, A; Garhofer, G; Kaya, S; Lasta, M; Palkovits, S; Pemp, B; Prager, F; Schmetterer, L; Schmidl, D, 2013
)
0.39
"The purpose of the study was to evaluate the effect of adding peripheral vasodilators, tolazoline, or papaverine, to transdermal drug delivery vehicles with the goal of improving the tissue bioavailability of transdermally delivered ibuprofen."( Vasomodulation influences on the transdermal delivery of Ibuprofen.
Carter, SG; Riviere, JE; Varadi, G; Veves, A; Zhu, Z, 2013
)
0.61
" Hence, the drug suffers from brief residence in the highly moving intestine during diarrhoea which leads to poor bioavailability and frequent dosing."( Design of innovated lipid-based floating beads loaded with an antispasmodic drug: in-vitro and in-vivo evaluation.
Adel, S; ElKasabgy, NA, 2014
)
0.4
" Researchers studied their impact on the bioavailability of active substances or on physical properties of tablets for many years."( [Influence of polymer type on the physical properties and the release study of papaverine hydrochloride from tablets].
Kasperek, R; Poleszak, E; Polski, A; Sobótka-Polska, K,
)
0.36
" Pharmacokinetic analysis showed that oral administration of a tablet composed of DIC and PAP do not change the pharmacokinetic parameters such as MRT, MAT, Cl and bioavailability of the active substances compared with single administration of DIC and PAP after single dose."( PHARMACOKINETICS OF DICLOFENAC SODIUM AND PAPAVERINE HYDROCHLORIDE AFTER ORAL ADMINISTRATION OF TABLETS TO RABBITS.
Jawień, W; Kasperek, R; Poleszak, E; Zimmer, Ł,
)
0.4
"NLGM1 protects against LC-induced human microvascular endothelial dysfunction through increased nitric oxide bioavailability and reduced oxidative and nitrative stress mediated by Nrf-2-dependent antioxidant stress response."( Monosialoganglioside-Containing Nanoliposomes Restore Endothelial Function Impaired by AL Amyloidosis Light Chain Proteins.
Blancas-Mejia, LM; Burciu, C; Franco, DA; Guzman-Villanueva, D; Hari, P; Karamanova, N; Lindsay, S; Migrino, RQ; Ramirez-Alvarado, M; Senapati, S; Truran, S; Weissig, V, 2016
)
0.43
"Papaverine hydrochloride loaded electrospun fibers were prepared for buccal drug delivery with the aim of improving the oral bioavailability of the crystalline drug, which can be achieved by the increased solubility and by the circumvention of the intensive first pass metabolism."( Prediction of the hydroxypropyl cellulose-poly(vinyl alcohol) ratio in aqueous solution containing papaverine hydrochloride in terms of drug loaded electrospun fiber formation.
Kazsoki, A; Szabó, P; Zelkó, R, 2017
)
2.11
"Papaverine hydrochloride loaded gels, films and electrospun fibers were prepared for buccal drug delivery with the aim of improving the oral bioavailability of the crystalline drug, which can be achieved by the increased solubility and by the circumvention of the intensive first pass metabolism."( Microstructural characterization of papaverine-loaded HPC/PVA gels, films and nanofibers.
Domján, A; Kazsoki, A; Süvegh, K; Zelkó, R, 2018
)
2.2
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Drotaverine hydrochloride (DRH) is a spasmolytic drug that suffers from brief residence due to intestinal hypermotility during diarrheal episodes associated with gastrointestinal colics resulting in low bioavailability and repeated dosing."( Drotaverine Hydrochloride Superporous Hydrogel Hybrid System: a Gastroretentive Approach for Sustained Drug Delivery and Enhanced Viscoelasticity.
Badawy, AA; Elmalak, NSA; Farag, MM; Louis, MM; Nessem, DI, 2022
)
0.72

Dosage Studied

Papaverine is suggested as an additional mode of therapy in the management of psychogenic impotence. No responder to PDE5-I that undergone to PDDU by PII at high dosage (bimix: prostaglandin E1 20 mcg, papaverine 20 mg)

ExcerptRelevanceReference
" The dose-response curve for the chronotropic action of phenylephrine was parallel to that of isoprenaline, whilst the dose-response curve for the inotropic action of phenylephrine was less steep than that of isoprenaline."( Characterization of adrenoceptors mediating positive inotropic responses in the ventricular myocardium of the dog.
Endoh, M; Shimizu, T; Yanagisawa, T, 1978
)
0.26
" The dose-response curve, the latent period and temperature dependence of HR induced by MCD-peptide were similar to those of HR induced by compound 48/80."( [Histamine-liberating action of MCD-peptide from bee venom].
Gushchin, IS; Martynov, VI; Miroshnikov, AI, 1977
)
0.26
" Furthermore the dose-response relationships for increases of cAMP and of developed tension elicited by phenylephrine were determined."( Relationship between the level of cAMP and the contractile force under stimulation of alpha- and beta-adrenoceptors by phenylephrine in the isolated rabbit papillary muscle.
Brodde, OE; Endoh, M; Schümann, HJ, 1976
)
0.26
" As with the time courses for isoprenaline, dose-response curves for the effect of isoprenaline and papaverine on cAMP content and force of contraction also appeared to be shifted towards higher levels at hypothemia."( The role of cyclic AMP in temperature-dependent changes of contractile force and sensitivity ot isoprenaline and papaverine in guinea-pig atria.
Brodde, OE; Butzheinen, R; Reinhardt, D; Schümann, HJ, 1978
)
0.69
" In these studies, it is shown that increasing concentrations of carbamylcholine (carbachol) result in a shift to the right of the dose-response curves to (-)-isoproterenol and (-)-soterenol and a reduction of the maximum degree of relaxation produced by these agonists relative to that produced by papaverine."( On the use of functional antagonism to estimate dissociation constants for beta adrenergic receptor agonists in isolated guinea-pig trachea.
Buckner, CK; Saini, RK, 1975
)
0.43
"The bioavailability of sustained-release papaverine HCl dosage forms were compared to equivalent doses of the drug administered as an elixir and conventional compressed tablets to 12 healthy human subjects."( The influence of dosage form on papaverine bioavailability.
Gollamudi, R; Meyer, MC; Straughn, AB,
)
0.68
" Dose-response curves for AII and the (2-8) peptide [angiotensin III (AIII)] indicate that AII is a more potent inhibitor of renin release than is AIII."( Inhibition of renin release from rat kidney slices by the angiotensins.
Naftilan, AJ; Oparil, S, 1978
)
0.26
"4 The dose-response curve to glucagon remained parallel in the presence of papaverine (2."( A new bioassay for glucagon.
Gagnon, G; Regoli, D; Rioux, F, 1978
)
0.49
" In response to intra-arterial injections of norepinephrine, hypertensive pigs (n = 8) demonstrated shifts in the dose-response curves to the left and lower vasoconstrictor thresholds than controls (n = 10)."( Structural and functional changes in vascular resistance and reactivity in the deoxycorticosterone acetate (DOCA)-hypertensive pig.
Berecek, KH; Bohr, DF, 1977
)
0.26
" Fusaric acid produced a shift to the right and down in the dose-response curves to all tested agonists, and antagonized acetylcholine and serotonin most effectively among these agonists."( Relaxation of isolated rabbit arteries by fusaric (5-butylpicolinic) acid.
Asano, M; Hidaka, H, 1976
)
0.26
" The dose-response curve for isoprenaline was shifted to the left by papaverine (3 times 10- minus 6 to 3 times 10- minus 5 M), in a dose-dependent manner, while that for calcium was not affected by the same concentration."( Effects of papaverine on isolated rabbit papillary muscle.
Endoh, M; Schümann, HJ, 1975
)
0.88
" The average effective dosage of papaverine and PGE1 was variable among the different groups."( Intracavernous self-injection therapy for the treatment of erectile dysfunction.
Chiang, HS; Chiang, WH; Wen, TC; Wu, CC, 1992
)
0.56
" Besides, the dosage of naomaitong is positively correlated to the effect and action of the drug."( [Influences of naomaitong upon cerebral blood flow in dogs].
Chang, L; Chen, X; He, G; Liu, J; Yang, J; Ye, S, 1992
)
0.28
" The initial dosage in pharmacological erection therapy may be adjusted according to these risk factors."( Risk factors for papaverine-induced priapism.
Jarow, JP; Lomas, GM, 1992
)
0.62
" E1-PG dosage varied from 10 to 40 mcg based on diagnosis, and was readjusted in 6 of the 9 patients which in the initial tests had not obtained sufficient erection, therefore bringing about a final 91."( [Prospective study of the effectiveness and side effects of intracavernous prostaglandin E1 versus papaverine or papaverine phentolamine in the diagnosis and treatment of erection dysfunction. Review of the literature].
Alvarez González, E; Chandeck Montesa, K; Chen Jiménez, J; Rodríguez Antolín, A; Tamayo, JC, 1992
)
0.5
" A portable home nocturnal tumescence monitor classification of severity of sexual dysfunction provided a guideline for the intracavernous pharmacological injection initial dosage and the probability of success or failure in patients who desire this form of therapy for male sexual dysfunction."( Classification of sexual dysfunction for management of intracavernous medication-induced erections.
Fein, RL, 1990
)
0.28
" Dose-dependent response with reversed drug sensitivity was found in the papaverine group, but only elongation to tumescence was found in the PGE1 group, even with double dosage (probably because of scarce PGE1 receptors in monkey's penile tissue)."( Histopathological change of corpora cavernosa after long-term intracavernous injection.
Chu, HW; Ho, WL; Hwang, TI; Yang, CR, 1991
)
0.51
" Theophylline, which at this dosage blunted the vasodilator effect of adenosine (the physiological agonist for the P1 purinoceptor), significantly increased lower-body negative pressure-mediated vasoconstriction."( Sympathetic nervous system-dependent vasoconstriction in humans. Evidence for mechanistic role of endogenous purine compounds.
Pedrinelli, R; Salvetti, A; Taddei, S, 1990
)
0.28
" A further advantage of the method is the lower dosage required, which means that the gonads are exposed to less radiation."( [Cavernosography using digital luminescence radiography (DLR) in the diagnosis of venous induced erectile function and of diseases of the corpus cavernosum].
Christiansen, GR; Marks, W; Papadopoulos, I; Weichert-Jacobsen, K, 1991
)
0.28
" Already the lowest dosage of papaverine (5 mg) was able to induce a maximal flow acceleration."( [Coronary reserve determination by intracoronary papaverine: effects of various doses on coronary circulation and hemodynamics].
Franz, N; Linss, G; Modersohn, D; Romaniuk, P,
)
0.67
"5 peak/resting velocity after a maximally vasodilating dose of intracoronary papaverine), the dose-response characteristics to intracoronary boluses and intravenous infusions of adenosine were similar to those found in normal patients."( Effects of adenosine on human coronary arterial circulation.
Christensen, BV; Laxson, DD; Wilson, RF; Wyche, K; Zimmer, S, 1990
)
0.51
" Use of low dosage of papaverine is suggested as an additional mode of therapy in the management of psychogenic impotence."( Intracavernous papaverine in the management of psychogenic impotence.
Bhutwala, A; Dhabuwala, CB; Kerkar, P; Kumar, A; Pierce, JM, 1990
)
0.95
" Dose-response curves to KCl and phenylephrine (PE) were constructed; the response to PE was significantly higher in DM than control arteries."( Contribution of the arterial tissue to vascular pathology in diabetes mellitus.
Carrara, MC, 1990
)
0.28
" After exact dosage adjustment the danger of drug-induced priapism is low."( [Priapism following intracavernous injection of vasoactive substances as a urologic emergency].
Papadopoulos, I; Wand, H; Weichert-Jacobsen, K, 1990
)
0.28
" The dosage of phentolamine mesylate-papaverin hydrochloride injection required was determined in each patient individually."( [Corpus cavernosum autoinjection therapy: initial experiences in erectile dysfunction].
Altwein, JE; Bähren, W; Gall, H; Gallwitz, A; Scherb, W; Stief, CG, 1986
)
0.27
"On isolated electrically stimulated left and spontaneously beating right guinea-pig atria the interaction between PDE-inhibitors and the positive inotropic and chronotropic action of orciprenaline, forskolin and histamine in dose-response curve was examined."( Interaction of phosphodiesterase inhibitors triamterene, papaverine, theophylline, IBMX and amrinone with other positive inotropic acting substances on isolated guinea-pig atria.
Greeff, K; Schmitt, M, 1987
)
0.52
" To minimize complications, careful selection of candidates, cautious dosage determination, and thorough instruction on injection technique are mandatory."( Vasoactive intracavernous pharmacotherapy.
Sidi, AA, 1988
)
0.27
" Furthermore, a chemical prosthesis is suitable mainly for the treatment of impotence due to diabetes, by adjusting the dosage and administration."( [Diagnosis and treatment of impotence with administration of chemical prosthesis using real-time mechanical sector duplex scanner--with special reference to diabetic patients].
Kaneda, S; Matsuoka, K; Nakajima, Y; Shibayama, T; Suzuki, Y; Yamamoto, H, 1989
)
0.28
" The naltrexone stimulus-generalization curve and dose-response curve for loss of body weight were shifted to the left by IBMX and Ro 20-1724, which produce quasi-withdrawal, but not by papaverine, which does not."( Phosphodiesterase inhibitors potentiate opiate-antagonist discrimination by morphine-dependent rats.
Holtzman, SG, 1989
)
0.47
"5 mM and 1 mM) also induces a displacement to the right of the dose-response curves to Ca2+, and the antagonism was not competitive."( Antioquine: a new bisbenzylisoquinoleine alkaloid with calcium antagonist activity.
Anselmi, E; Candenas, ML; Cortes, D; D'Ocon, MP; Zafra-Polo, MC,
)
0.13
" Sixteen volunteers who were taught to self-administer the solution, injected the preadjusted dosage into the corpus cavernosum each time before the intended sexual act."( Papaverine-induced erection.
Götz, F; Székely, J; Török, A, 1989
)
1.72
" It was proved that an adequate dosage of papaverine autoinjections into a spongy body was a simple, safe and effective method to cure erectile impotency, especially in patients with nonadvanced psychoneurological or vasculogenic disorders."( [Induction of an erection using papaverine].
Getz, F; Sekei, J; Terek, A,
)
0.68
" The effects of these drugs on the basal tension, on dose-response curves for muscle contraction produced by histamine and on cAMP level were investigated in guinea pig trachea, together with their influence on the resting and histamine-evoked mechanical and membrane activities of dog trachea."( The effects of methylxanthines, ethymizol, ephedrine and papaverine on guinea pig and dog trachea.
Bauer, V; Bilcíková, L; Kolena, J, 1987
)
0.52
" At this dosage prostaglandin E1 was most effective in inducing artificial penile erection (11 of 12 patients)."( Efficiency and side effects of prostaglandin E1 in the treatment of erectile dysfunction.
Schramek, P; Waldhauser, M, 1988
)
0.27
" Intracoronary adenosine is a potent and very short acting vasodilator for studying coronary flow reserve, but the side effects and unpredictability of the dosage needed to produce maximal hyperemia may limit its applicability."( Value and limitations of intracoronary adenosine for the assessment of coronary flow reserve.
Juillière, Y; Roelandt, JR; Serruys, PW; Zijlstra, F, 1988
)
0.27
" Two patients who failed to achieve erections had the lowest penile brachial index values and 1 in whom priapism developed had the highest value, indicating that this may be a useful technique to determine the initial dosage of the injection."( Pharmacological treatment of erectile dysfunction after radical prostatectomy.
Dennis, RL; McDougal, WS, 1988
)
0.27
" We related their penis-brachial pressure index (PBPI) with the dosage of papaverine necessary to obtain a full erection as measured by tumistore."( Penile-brachial pressure index as a guide for the dosage of intracavernous injection of papaverine.
Caviglia, C; de Rose, AF; Germinale, F; Giuliani, L; Pittaluga, P; Puppo, P, 1988
)
0.73
" Careful investigation of erectile disturbances and search for the appropriate papaverin dosage are therefore crucial."( [Diagnosis and therapy of erectile impotence with special reference to papaverine].
Schnyder von Wartensee, M; Studer, UE, 1986
)
0.5
" The tested medication has a favorable therapeutic spectrum as a result of the low dosage of the individual substances."( [Bronchospasmolytic effectiveness of controlled drug combinations].
Forche, G; Harnoncourt, K; Zenker, G, 1986
)
0.27
" In this study we used a subselective coronary Doppler catheter to measure the dose-response kinetics of a shorter acting vasodilator, intracoronary papaverine."( Intracoronary papaverine: an ideal coronary vasodilator for studies of the coronary circulation in conscious humans.
White, CW; Wilson, RF, 1986
)
0.83
" Serum samples from healthy volunteers dosed orally with bencyclane fumarate were analyzed by both of the radioimmunoassay and gas chromatography-mass spectrometric methods."( Radioimmunoassay of bencyclane in human serum.
Kawahara, K; Mohri, Z; Shono, F; Yasuda, T; Yoshitake, A, 1985
)
0.27
"1 to 1 mM) or verapamil (3 to 30 nM) induced parallel, concentration-dependent rightward displacements of the dose-response curves to Ca2+ (0."( Ketamine-inhibition of calcium-induced contractions in depolarized rat uterus: a comparison with other calcium antagonists.
Calixto, JB; Loch, S, 1985
)
0.27
" Dose-response curves were constructed for five agents."( The effectiveness of local injections of vasodilating agents to produce vasodilation in subcutaneous tissue in rabbits.
DeYoung, NJ; Duncan, HJ; Faris, IB, 1985
)
0.27
" Dose-response curves to intra-arterial administration of arachidonic acid (12 to 200 microgram kg-1), bradykinin (0."( Responses to arachidonic acid and other dilator agonists and their modification by inhibition of prostaglandin synthesis in the canine hindlimb.
Morcillo, E, 1980
)
0.26
" Within a limited dose range, linear/log dose-response curves can be obtained after application of histamine or bradykinin."( Use of 125I-labeled human serum albumin for quantitation of microvascular permeability in rat skin: reevaluation of an old method for studies on substances with an enhancing effect on microvascular permeability.
Gerdin, B, 1981
)
0.26
" The dose-response curve for isoprenaline was shifted to the right and downward in the presence of YC-93 in a concentration-dependent manner, and the positive inotropic action of calcium was also inhibited markedly by YC-93."( Dissociation of cyclic AMP and contractile responses to isoprenaline: effects of a dihydropyridine derivative, nicardipine (YC-93), on canine ventricular muscle.
Endoh, M; Taira, N; Yanagisawa, T, 1980
)
0.26
" Papaverine and theophylline caused a decrease both in the maximum height and the slope of dose-response curves induced by the three stimulants, and an increase in the cyclic AMP levels."( Smooth muscle relaxing drugs and guinea pig ileum.
Goto, J; Mukai, T; Takagi, K; Yamaguchi, E, 1981
)
1.17
" Cinnarizine potentiated the effect of PGI2 shifting the anti-hypoxic dose-response curve of PGI2 to the left."( Study on the anti-hypoxic effect of cinnarizine and its interaction with prostacyclin.
Milanova, D; Nikolov, R; Nikolova, M, 1984
)
0.27
" This action carried over to ex vivo situation following intraduodenal dosing as demonstrated in rabbits."( Inhibition of platelet aggregation by a new agent, 2,2'-dithiobis-(N-2-hydroxypropyl benzamide) (KF4939).
Nakamizo, N; Shuto, K; Yamada, K, 1983
)
0.27
" TM-906 noncompetitively antagonized the contractile response to methacholine, and it caused a parallel shift of dose-response curves for the contractile response to CaCl2 to higher concentrations."( Effects of trimebutine maleate (TM-906) on the smooth muscles of isolated guinea pig gallbladder.
Magaribuchi, T; Takenaga, H; Tamaki, H, 1984
)
0.27
" ALK-1 and papaverine promoted a dose-dependent flattening of the dose-response curves obtained to acetylcholine and histamine on ileum strips and of the dose-response curves to acetylcholine and oxytocin on uterine strips."( Antispasmodic effects of an alkaloid extracted from Phyllanthus sellowianus: a comparative study with papaverine.
Calixto, JB; Neto, AS; Rae, GA; Valle, RM; Yunes, RA, 1984
)
0.87
" Statistically significant dose-response relationships were always observed, but with one exception, no differences were found between the contractile responses (norepinephrine, serotonin, prostaglandin F2 alpha) or the dilating responses (papaverine) in diabetic vs normal mice."( Microvascular responses of intermediate-size arterioles on the cerebral surface of diabetic mice.
Levasseur, JE; Rosenblum, WI, 1984
)
0.45
" This dosage produced a minimal increase in heart rate and reduced the PR interval."( The search for a digitalis substitute II milrinone (Win 47203). Its action on the heart-lung preparation of the dog.
Farah, A; Kabela, E; Mendez, R; Pastelin, G, 1983
)
0.27
" Based on the results obtained and pharmacokinetic properties, the expectable optimal dosage and formulations for the possible field of indication were elaborated."( Biopharmaceutical aspects of Depogen.
Marton, S; Szentmiklósi, P, 1983
)
0.27
" The dose-response curve for Phe was markedly shifted to the left by papaverine in 6W rats, but slightly in 7M rats."( Age-dependent differences in the positive inotropic effect of phenylephrine on rat isolated atria.
Hashimoto, H; Nakashima, M; Sugino, N, 1983
)
0.5
" Similar effects were observed on guinea-pig "in vitro" stomach preparation where PM2 and Papaverine were ineffective in modifying Histamine dose-response curves and PM3 reduced significantly maximal peak effects of Histamine, behaving as a non-competitive antagonist."( [Pharmacological actions of alkylaminoalkyl-phenylbenzisothazole compounds on the gastrointestinal tract].
Barocelli, E; Bordi, F; Chiavarini, M; Impicciatore, M; Morini, G; Plazzi, P, 1984
)
0.49
"The dissolution profiles of 11 commercially available papaverine, phenytoin, and sulfisoxazole dosage forms were determined using a dissolution simulator."( In vivo-in vitro correlations with a commercial dissolution simulator II: papaverine, phenytoin, and sulfisoxazole.
Meyer, MC; Yau, MK, 1983
)
0.75
" In a dose-response experiment the tumour and subcutaneous vascular beds seemed to be equally sensitive to noradrenaline."( Influence of vasoactive drugs on local tumor blood flow.
Lilja, J; Mattsson, J; Peterson, HI, 1982
)
0.26
" In lower concentrations (10(-6)-10(-5) M), the compounds did not affect the dose-response curves of carbachol and isoprenaline."( Antispasmodic effects of valeriana compounds: an in-vivo and in-vitro study on the guinea-pig ileum.
Hazelhoff, B; Malingré, TM; Meijer, DK, 1982
)
0.26
" Incubation of tissues with papaverine (1 hr) changed the usual dose-response curve to isoproterenol into a low, monotonous effect, independent of the agonist dose."( Papaverine-induced changes on cardiac inotropism with special reference to a D-propranolol antagonism.
Aramendía, P; Márquez, MT, 1982
)
2
"3 Pretreatment of the mice with naloxone caused a dose-dependent shift to the right of the dose-response curve to morphine."( Evidence for an action of morphine and the enkephalins on sensory nerve endings in the mouse peritoneum.
Bentley, GA; Newton, SH; Starr, J, 1981
)
0.26
" From dose-response curves it was demonstrated that epinine produced an increase in amplitude and duration of the plateau, and in duration of the action potential."( Electrophysiological and mechanical studies of frog heart adrenoceptor stimulation by epinine.
Rakotonirina, A; Soustre, H, 1981
)
0.26
" The current report provides a replicatin of the original experiments and also an extension of the work to complete dose-response curves for salsolinol and THP."( A critical evaluation of tetrahydroisoquinoline induced ethanol preference in rats.
Deitrich, RA; Duncan, C, 1980
)
0.26
" Of the 68 spinal cord injured men in whom treatment with papaverine was initiated a therapeutic dosage was determined in 50 (74%)."( Management of impotence due to spinal cord injury using low dose papaverine.
Chen, D; Lovell, L; Palmer, J; Rayner, S; Roth, EJ; Yarkony, GM, 1995
)
0.77
" To measure the dose-response kinetics of bolus injections of intracoronary nicorandil and to compare the vasodilatory response to nicorandil with that of intracoronary papaverine in humans, coronary blood flow velocity was measured in 30 patients using a 3Fr intravascular Doppler catheter."( Coronary microvascular response to intracoronary administration of nicorandil.
Hongo, M; Nakatsuka, T; Sekiguchi, M; Takenaka, H; Uchikawa, S; Watanabe, N, 1995
)
0.49
" Therapeutic indications for auto-injections require careful choice of the agent and the dosage to inject depending on the cause of the impotence and the patient's demands and capacity to learn the technique."( [Diagnosis and treatment of impotence. Indications of intracavernous injections].
Benoît, G; Blanchet, P; Giuliano, F; Jardin, A, 1994
)
0.29
" Three dosage levels (1."( [Effects of scoparone on hemodynamics in anesthetized rabbits].
Huang, JC; Sun, AX; Wang, RX; Wang, XR, 1993
)
0.29
" These results indicate that inhalational administration of a selective PDE isoenzyme type III/IV inhibitor, SDZ ISQ 844 decreases airway responsiveness at dosage which does not affect the base-line respiratory resistance."( [Effects of inhaled SDZ ISQ 844, a cyclic nucleotide phosphodiesterase isoenzyme type III/IV inhibitor, on airway responsiveness in beagles].
Adachi, M; Horikoshi, S; Idaira, K; Imai, T; Okamoto, M, 1994
)
0.29
" Techniques of injection, dosing and followup are discussed."( Experience with intracavernosal tri-mixture for the management of neurogenic erectile dysfunction.
Chao, R; Clowers, DE, 1994
)
0.29
" Analysis of some commercial dosage forms containing one of these congeners showed good recovery with sufficient accuracy and precision."( Ion-pair reversed-phase liquid chromatographic identification and quantitation of papaverine congeners.
Girgis, EH, 1993
)
0.51
" We describe the procedure to establish the dosage for home use and discuss the implications of the low dosages relative to previous reports."( Intracavernous pharmacotherapy for impotence: selection of appropriate agent and dose.
Donatucci, CF; Kaula, N; Lue, TF; von Heyden, B, 1993
)
0.29
" Dose-response analysis yielded an apparent EC50 for R59022-induced oocyte maturation of approximately 15 microM."( Analysis of R59022 actions in Xenopus laevis oocytes.
Frith, T; Sadler, SE; Wasserman, WJ, 1996
)
0.29
" On successive visits, the patient injects himself and the dosage is titrated until a satisfactory erection is obtained."( A simplified pharmacologic erection program for patients with spinal cord injury.
Britanico, J; Galea, G; Nicolis, C; Vapnek, JM; Zaslau, S, 1999
)
0.3
" This progressive method of treatment enabled us to select the optimal dosage and combinations of compounds in 441/452 patients (97."( [Evaluation of 452 patients with erectile dysfunction treated by combinations of vasoactive agents by penile injection].
Baniel, J; Israilov, S; Livne, P; Segenreich, E; Shmueli, J; Simon, D, 1998
)
0.3
" Dilations to sodium nitroprusside and C-type natriuretic peptide were significantly reduced (by 10+/-2% and 35+/-6%), whereas dose-response curves for papaverine and ACh were shifted to the right, despite unchanged increases in endothelial Ca(2+) after ACh."( Oxidized LDL increases the sensitivity of the contractile apparatus in isolated resistance arteries for Ca(2+) via a rho- and rho kinase-dependent mechanism.
Bolz, SS; de Wit, C; Derwand, R; Galle, J; Pohl, U, 2000
)
0.51
" Cumulative dose-response curves to bradykinin induced an important vasodilation in NTRs, with a maximal response that remained unaffected in the presence of either NNLA (30 pmol/I), indomethacin (10 pmol/l) or the two combined."( Altered coronary dilation in deoxycorticosterone acetate-salt hypertension.
de Champlain, J; Lamontagne, D; Millette, E, 2000
)
0.31
" The dose-response curve for NE (0."( Lead-cadmium interaction effect on the responsiveness of rat mesenteric vessels to norepinephrine and angiotensin II.
Andrzejak, R; Skoczyńska, A; Wróbel, J, 2001
)
0.31
" Previously others have suggested that repeat dosing with vasoactive medication may improve the diagnostic accuracy of vascular testing."( Improving the accuracy of vascular testing in impotent men: correcting hemodynamic alterations using a vasoactive medication re-dosing schedule.
Abdel-Moneim, A; Abobakr, R; Goldstein, I; Mulhall, JP, 2001
)
0.31
" The injections were then repeated with increasing dosage to archive a rigid erection."( [Intracavernous injections in the treatment of erectile dysfunction in spinal cord injured patients: experience with 36 patients].
Boiteau, F; Boyer, F; Dizien, O; Laffont, I; Lebib Ben Achour, S, 2001
)
0.31
" Rigiscan was used for the objective determination of the initial dosage and then doses were regulated in order to introduce an erection suitable for penetration and maintenance of erection for 30 min."( Diabetic impotence treated by intracavernosal injections: high treatment compliance and increasing dosage of vaso-active drugs.
Athanasopoulos, A; Barbalias, G; Gyftopoulos, K; Perimenis, P, 2001
)
0.31
" Frequent follow-up visits and the adjustment of dosage to continue the success of therapy may prevent patient dissatisfaction and drop-out from treatment."( Diabetic impotence treated by intracavernosal injections: high treatment compliance and increasing dosage of vaso-active drugs.
Athanasopoulos, A; Barbalias, G; Gyftopoulos, K; Perimenis, P, 2001
)
0.31
"A precise and specific 1H-NMR method has been developed for the assay of papaverine hydrochloride (1) as a bulk drug, as well as in tablet and injection dosage forms."( 1H-NMR assay of papaverine hydrochloride and formulations.
Aboutabl, EA; Afifi, MS; Ei-Azzouny, AA,
)
0.71
" We found a shift in the dose-response curve of only phosphodiesterase 5 inhibitors."( The effect of chronic renal failure on phosphodiesterase inhibitor-induced relaxation responses in rabbit cavernosal strips.
Bagcivan, I; Gokce, G; Kilicarslan, H; Sarac, B; Sarioglu, Y; Yildirim, S, 2003
)
0.32
"The present study evaluates the effect of oral administration of papaverine at differential dosing regimens (100 mg/kg bw and 200 mg/kg bw) on the hepatic and pulmonary glutathione S-transferase (GST) activity and glutathione content (GSH) in male Wistar rats."( Papaverine, an opium alkaloid influences hepatic and pulmonary glutathione S-transferase activity and glutathione content in rats.
Aneja, R; Chandra, R; Dass, SK; Sharma, A; Talwar, A,
)
1.81
" Drug dosage was the same for both groups and routine bypass grafting was performed."( Papaverine delivery to the internal mammary artery pedicle effectively treats spasm.
Crawford, FA; Crumbley, AJ; Girard, DS; Kratz, JM; Sutton, JP; Williams, TH; Zellner, JL, 2004
)
1.77
" We set out to evaluate the impact of varying the ingredient dosage on response and short-term safety of Tx compared with PgE1."( A prospective randomized study to optimize the dosage of trimix ingredients and compare its efficacy and safety with prostaglandin E1.
Akhras, AA; Mohamed, K; Rashwan, H; Seyam, R,
)
0.13
"A topical dosing of MOX to posterior regions of the eye seems feasible."( Tissue distribution of moxaverine-hydrochloride in the rabbit eye and plasma.
Becker, U; Ehrhardt, C; Gukasyan, HJ; Kim, KJ; Lee, VH; Lehr, CM; Schaefer, UF, 2005
)
0.33
" Real time rigidity assessment was used for the objective determination of the initial dosage and then doses were regulated in order to introduce an erection suitable for penetration and maintenance of erection for approximately 30 min."( Long-term treatment with intracavernosal injections in diabetic men with erectile dysfunction.
Athanasopoulos, A; Gyftopoulos, K; Kartsanis, G; Konstantinopoulos, A; Liatsikos, E; Perimeni, PP; Perimenis, P, 2006
)
0.33
" The key point for maintenance in treatment is the adjustment of the therapeutic method and dosage to optimal levels for satisfactory erections."( Long-term treatment with intracavernosal injections in diabetic men with erectile dysfunction.
Athanasopoulos, A; Gyftopoulos, K; Kartsanis, G; Konstantinopoulos, A; Liatsikos, E; Perimeni, PP; Perimenis, P, 2006
)
0.33
" The proposed methods were checked using laboratory-prepared mixtures and were successfully applied for the analysis of pharmaceutical formulations containing the above drugs with no interference from other dosage form additives."( Determination of nifuroxazide and drotaverine hydrochloride in pharmaceutical preparations by three independent analytical methods.
Abdelkawy, M; Metwally, FH; Naguib, IA,
)
0.13
" The potential salt form would ideally decrease the rate of (SBE)7M-beta-CD release from osmotic pump formulations and result in an increase in the rate and extent of drug release in osmotic pump tablet and pellet dosage forms."( Evaluation of various properties of alternative salt forms of sulfobutylether-beta-cyclodextrin, (SBE)7M-beta-CD.
Haslam, JL; Sotthivirat, S; Stella, VJ, 2007
)
0.34
" The influence of excipients and of a size of the solid dosage forms on the amount of the released substances at the intervals of time using the different rates of flow of the dissolution medium was investigated."( Simultaneous release of diclofenac sodium and papaverine hydrochloride from tablets and pellets using the flow-through cell apparatus described by dimensionless equations.
Kasperek, R,
)
0.39
" In the PGE1-only group, the maintenance dosage was significantly correlated with preoperative sexual function and nerve sparing (NS) (P<0."( Experience with intracavernous injection in the treatment of erectile dysfunction after radical prostatectomy: dose considerations.
Cha, TL; Chuang, FP; Lakin, M; Montague, DK; Sun, GH; Wu, ST,
)
0.13
" Phenylephrine dose-response contraction was obtained after 1, 2, and 3 h in segments pre-incubated with DETA-NONOate or papaverine for 30 min."( Effect of DETA-NONOate and papaverine on vasodilation of human internal mammary artery.
Ansari, M; Dehpour, AR; Javadi-Paydar, M; Rabbani, S; Rahimi, N; Sohanaki, H; Tafti, SH, 2011
)
0.87
"Gelucire® 43/01 /isopropylmyristate-based calcium alginate floating beads coated with ethylcellulose using either PEG 400 or TEC as plasticizers proved to be a successful dosage form in extending DRT release."( Design of innovated lipid-based floating beads loaded with an antispasmodic drug: in-vitro and in-vivo evaluation.
Adel, S; ElKasabgy, NA, 2014
)
0.4
" Fourteen septic shock patients admitted to the Peking University Third Hospital were included in the study, and each patient received 30 mg papaverine, which is the approximate dosage used to treat a conventional arterial spasm."( Papaverine improves sublingual blood flow in patients with septic shock.
Li, H; Wang, Z; Yao, G; Zhu, X, 2015
)
2.06
"The capsule is one of the most important solid dosage forms in the pharmaceutical industry."( Influence of Polymer Type on the Physical Properties and Release Profile of Papaverine Hydrochloride From Hard Gelatin Capsules.
Iwaniak, K; Kasperek, R; Modrzewska, J; Poleszak, E; Polski, A; Sobótka-Polska, K; Sławińska, K,
)
0.36
"2), in absence of vascular risk factors, no responder to PDE5-I that undergone to PDDU by PII at high dosage (bimix: prostaglandin E1 20 mcg, papaverine 20 mg)."( Penile vascular diagnostic categorization using penile duplex Doppler ultrasound: Differences in vascular hemodynamics parameters by differences in anatomic sampling location.
Pezzoni, F; Scroppo, FI, 2016
)
0.64
" Our objective of this report is to raise awareness of this complication as well as to review the literature on periarterial papaverine use and the dosing for topical applications."( Periarterial papaverine to treat renal artery vasospasm during robot-assisted laparoscopic partial nephrectomy.
Cadeddu, JA; Sorokin, I; Stevens, SL, 2018
)
1.06
" Papaverine was given by intramuscular injection to all patients at a dosage of 90 mg/day postoperatively."( Antithrombotic Therapies in Digit Replantation with Papaverine Administration: A Prospective, Observational Study.
Zheng, X; Zhu, H; Zhu, X, 2017
)
1.62
" Drug dosage was the same for both groups."( Effect of Papaverine on Left Internal Mammary Artery Flow: Topical Spraying versus Perivascular Injection Method.
G S, V; Gowda, G; Kumar, J; Mathew, AK; Nanjappa, MC, 2020
)
0.96
" Thus, in order to adjust the dosage of OXY for well-managed pain relief with less toxicity, we tried establishing and validating a system for measuring plasma concentrations of OXY using liquid chromatography-tandem mass spectrometry (LC-MS/MS)."( Establishment to measure oxycodone in plasma with liquid chromatography-tandem mass spectrometry.
Ito, S; Kitaichi, K; Matsuo, M; Mori, M; Oida, Y; Soda, M; Yamasaki, R, 2022
)
0.72
" The rate of cardiac self-recovery and the dosage of dopamine were observed."( Papaverine Infusion Through Aortic Root before Cardiac Self-recovery in Heart Valve Replacement with TiO2 Nanocrystalline Film Material.
He, G; Jin, W; Lai, Y; Li, J; Mei, B; Tan, X; Wang, Y; Wei, S, 2022
)
2.16
"The novel SVEM experimental design methodology is exploited here exclusively to optimize the composition of four eco-friendly PVC membranes augmented by a computationally designed magnetic molecularly imprinted polymer to quantitatively determine drotaverine hydrochloride (DVN) in its combined dosage form and human plasma."( Computer-Aided Design of Eco-Friendly Imprinted Polymer Decorated Sensors Augmented by Self-Validated Ensemble Modeling Designs for the Quantitation of Drotaverine Hydrochloride in Dosage Form and Human Plasma.
A Abdel Salam, R; Abdelshakour, MA; Attala, K; E Mostafa, A; Eissa, MS; Elsonbaty, A; M Hadad, G, 2023
)
0.91
" Moreover, the proposed sensors showed ultimate eco-friendliness and selectivity for their target in its combined dosage form and spiked human plasma."( Computer-Aided Design of Eco-Friendly Imprinted Polymer Decorated Sensors Augmented by Self-Validated Ensemble Modeling Designs for the Quantitation of Drotaverine Hydrochloride in Dosage Form and Human Plasma.
A Abdel Salam, R; Abdelshakour, MA; Attala, K; E Mostafa, A; Eissa, MS; Elsonbaty, A; M Hadad, G, 2023
)
0.91
"The proposed sensors were validated in accordance with International Union of Pure and Applied Chemistry (IUPAC) recommendations, proving their sensitivity and selectivity for drotaverine determination in dosage form and human plasma."( Computer-Aided Design of Eco-Friendly Imprinted Polymer Decorated Sensors Augmented by Self-Validated Ensemble Modeling Designs for the Quantitation of Drotaverine Hydrochloride in Dosage Form and Human Plasma.
A Abdel Salam, R; Abdelshakour, MA; Attala, K; E Mostafa, A; Eissa, MS; Elsonbaty, A; M Hadad, G, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
vasodilator agentA drug used to cause dilation of the blood vessels.
antispasmodic drugA drug that suppresses spasms. These are usually caused by smooth muscle contraction, especially in tubular organs. The effect is to prevent spasms of the stomach, intestine or urinary bladder.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
benzylisoquinoline alkaloidAny isoquinoline alkaloid based on a benzylisoquinoline skeleton.
isoquinolinesA class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives.
dimethoxybenzeneAny methoxybenzene that consists of a benzene skeleton substituted with two methoxy groups and its derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
papaverine biosynthesis312
papaverine biosynthesis313

Protein Targets (82)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glp-1 receptor, partialHomo sapiens (human)Potency10.32250.01846.806014.1254AID624148
thioredoxin reductaseRattus norvegicus (Norway rat)Potency0.33590.100020.879379.4328AID488773; AID588453
15-lipoxygenase, partialHomo sapiens (human)Potency39.81070.012610.691788.5700AID887
phosphopantetheinyl transferaseBacillus subtilisPotency2.81840.141337.9142100.0000AID1490
Fumarate hydrataseHomo sapiens (human)Potency37.22120.00308.794948.0869AID1347053
NFKB1 protein, partialHomo sapiens (human)Potency10.00000.02827.055915.8489AID895; AID928
GLS proteinHomo sapiens (human)Potency0.56230.35487.935539.8107AID624146
PPM1D proteinHomo sapiens (human)Potency0.41540.00529.466132.9993AID1347411
TDP1 proteinHomo sapiens (human)Potency13.33590.000811.382244.6684AID686978; AID686979
ThrombopoietinHomo sapiens (human)Potency12.58930.02517.304831.6228AID917; AID918
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency3.54810.011212.4002100.0000AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency6.25590.00137.762544.6684AID914; AID915
thyroid stimulating hormone receptorHomo sapiens (human)Potency7.67290.001318.074339.8107AID926; AID938
EWS/FLI fusion proteinHomo sapiens (human)Potency21.63900.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
polyproteinZika virusPotency37.22120.00308.794948.0869AID1347053
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency3.16570.035520.977089.1251AID504332
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency15.90270.00207.533739.8107AID891
hexokinase-4 isoform 1Homo sapiens (human)Potency0.70792.511913.800328.1838AID743205
polyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)Potency7.07951.000012.232631.6228AID1452
cytochrome P450 2C19 precursorHomo sapiens (human)Potency6.33100.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency26.20000.00636.904339.8107AID883
atrial natriuretic peptide receptor 1 precursorHomo sapiens (human)Potency23.93410.134610.395030.1313AID1347049
chromobox protein homolog 1Homo sapiens (human)Potency0.00600.006026.168889.1251AID488953
glucokinase regulatory proteinHomo sapiens (human)Potency0.70792.511913.800328.1838AID743205
mitogen-activated protein kinase 1Homo sapiens (human)Potency19.78310.039816.784239.8107AID995
atrial natriuretic peptide receptor 2 precursorHomo sapiens (human)Potency13.09180.00669.809418.4927AID1347050
ubiquitin carboxyl-terminal hydrolase 2 isoform aHomo sapiens (human)Potency12.58930.65619.452025.1189AID927
ras-related protein Rab-9AHomo sapiens (human)Potency91.99970.00022.621531.4954AID485297
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency13.59200.00798.23321,122.0200AID2546; AID2551
DNA polymerase kappa isoform 1Homo sapiens (human)Potency4.10400.031622.3146100.0000AID588579
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency1.54720.005612.367736.1254AID624032
survival motor neuron protein isoform dHomo sapiens (human)Potency7.94330.125912.234435.4813AID1458
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency2.25360.031610.279239.8107AID884; AID885
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency3.99970.00106.000935.4813AID943; AID944
lamin isoform A-delta10Homo sapiens (human)Potency1.99530.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency2.25361.000012.224831.6228AID885
Interferon betaHomo sapiens (human)Potency0.41540.00339.158239.8107AID1347411
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency2.25361.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency2.25361.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency2.25361.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency2.25361.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency2.25361.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency2.25361.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency2.25361.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency2.25361.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency2.25361.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency2.25361.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency26.20000.00638.235039.8107AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency2.25361.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency2.25361.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency2.25361.000012.224831.6228AID885
Disintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)Potency12.58931.584913.004325.1189AID927
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency17.78281.000010.475628.1838AID1457
GABA theta subunitRattus norvegicus (Norway rat)Potency2.25361.000012.224831.6228AID885
CREB-binding proteinHomo sapiens (human)Potency5.69040.02822.360012.5893AID905; AID906; AID907; AID916
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency2.25361.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10ARattus norvegicus (Norway rat)IC50 (µMol)0.07600.07600.07600.0760AID977608
cGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)IC50 (µMol)14.76670.00001.77679.2000AID158293; AID158598; AID1799753
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)23.13000.20005.677410.0000AID1473741
High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)IC50 (µMol)25.00000.00001.85239.2000AID1799753
cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)IC50 (µMol)16.90000.00001.18439.6140AID1799753; AID220176
3',5'-cyclic-AMP phosphodiesterase Sus scrofa (pig)IC50 (µMol)1.70000.00103.40026.4000AID158589
Bile salt export pumpHomo sapiens (human)IC50 (µMol)92.66670.11007.190310.0000AID1443980; AID1449628; AID1473738
Vascular endothelial growth factor receptor 1 Homo sapiens (human)IC50 (µMol)24.33000.00010.29147.0000AID263610
AcetylcholinesteraseHomo sapiens (human)IC50 (µMol)24.33000.00000.933210.0000AID263610
cAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)IC50 (µMol)1.60000.00001.068010.0000AID1557505
Cytochrome P450 2C19Homo sapiens (human)IC50 (µMol)0.76200.00002.398310.0000AID625247
Serine hydroxymethyltransferase, mitochondrialHomo sapiens (human)IC50 (µMol)2.69150.43653.58839.7700AID1619186
Vascular endothelial growth factor receptor 3Homo sapiens (human)IC50 (µMol)24.33000.00010.22644.9000AID263610
Vascular endothelial growth factor receptor 2Homo sapiens (human)IC50 (µMol)24.33000.00000.48308.8000AID263610
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)IC50 (µMol)15.30000.23002.510510.0000AID158892; AID220175
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)IC50 (µMol)15.30000.00002.14179.2000AID158892; AID220175
cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)IC50 (µMol)13.20000.00001.146310.0000AID1625381; AID1799753
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)7.24440.00091.901410.0000AID576612
cGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)IC50 (µMol)1.03000.00002.072410.0000AID615721
cGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)Ki0.28250.00500.33811.4000AID1797286; AID275401
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)IC50 (µMol)15.30000.23001.98149.0000AID158892; AID220175
cGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)IC50 (µMol)5.55760.00031.990110.0000AID1552312; AID1557504; AID1799753; AID615720; AID705188
cGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)Ki0.24800.00500.32091.4000AID1797286; AID275400
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Rattus norvegicus (Norway rat)IC50 (µMol)0.03600.00020.01340.0360AID1267450; AID1395054; AID1542676; AID615724
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Rattus norvegicus (Norway rat)Ki0.23770.00020.17830.4170AID1797286
Phosphodiesterase Sus scrofa (pig)IC50 (µMol)0.62000.62000.73150.8430AID158594
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AHomo sapiens (human)IC50 (µMol)0.07000.00001.49049.2000AID1140225; AID1190578; AID1542658; AID1552311; AID1727165; AID484805; AID550507; AID598564; AID615719; AID650201; AID705199; AID767814
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AHomo sapiens (human)IC20 (µMol)0.65000.65000.65000.6500AID1743696
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (334)

Processvia Protein(s)Taxonomy
heart valve developmentcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
ventricular septum developmentcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
aorta developmentcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwaycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
regulation of cGMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cAMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to macrophage colony-stimulating factor stimuluscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of vascular permeabilitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
positive regulation of vascular permeabilitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
regulation of cAMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP catabolic processcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
positive regulation of inflammatory responsecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
establishment of endothelial barriercGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to mechanical stimuluscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to cAMPcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to cGMPcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to transforming growth factor beta stimuluscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to 2,3,7,8-tetrachlorodibenzodioxinecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
positive regulation of gene expressioncGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of cGMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of cAMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
regulation of mitochondrion organizationcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP catabolic processHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
regulation of DNA-templated transcriptionHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
cellular response to epidermal growth factor stimulusHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
cAMP-mediated signalingHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
positive regulation of cardiac muscle hypertrophycGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
regulation of nitric oxide mediated signal transductioncGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
T cell proliferationcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of T cell proliferationcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP catabolic processcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
oocyte developmentcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of cardiac muscle contractioncGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
relaxation of cardiac musclecGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
positive regulation of oocyte developmentcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cAMP-mediated signalingcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
angiogenesisVascular endothelial growth factor receptor 1 Homo sapiens (human)
monocyte chemotaxisVascular endothelial growth factor receptor 1 Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of cell population proliferationVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of phospholipase C activityVascular endothelial growth factor receptor 1 Homo sapiens (human)
cell migrationVascular endothelial growth factor receptor 1 Homo sapiens (human)
peptidyl-tyrosine phosphorylationVascular endothelial growth factor receptor 1 Homo sapiens (human)
cell differentiationVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of cell migrationVascular endothelial growth factor receptor 1 Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusVascular endothelial growth factor receptor 1 Homo sapiens (human)
vascular endothelial growth factor receptor-1 signaling pathwayVascular endothelial growth factor receptor 1 Homo sapiens (human)
vascular endothelial growth factor signaling pathwayVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of MAP kinase activityVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of MAPK cascadeVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of angiogenesisVascular endothelial growth factor receptor 1 Homo sapiens (human)
protein autophosphorylationVascular endothelial growth factor receptor 1 Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayVascular endothelial growth factor receptor 1 Homo sapiens (human)
blood vessel morphogenesisVascular endothelial growth factor receptor 1 Homo sapiens (human)
embryonic morphogenesisVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionVascular endothelial growth factor receptor 1 Homo sapiens (human)
negative regulation of vascular endothelial cell proliferationVascular endothelial growth factor receptor 1 Homo sapiens (human)
hyaloid vascular plexus regressionVascular endothelial growth factor receptor 1 Homo sapiens (human)
multicellular organism developmentVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of kinase activityVascular endothelial growth factor receptor 1 Homo sapiens (human)
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
cAMP catabolic processcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
signal transductioncAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
G protein-coupled receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
sensory perception of smellcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
regulation of protein kinase A signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cellular response to xenobiotic stimuluscAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cAMP-mediated signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 2C19Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C19Homo sapiens (human)
steroid metabolic processCytochrome P450 2C19Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C19Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C19Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
regulation of oxidative phosphorylationSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
glycine metabolic processSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
L-serine metabolic processSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
L-serine biosynthetic processSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
one-carbon metabolic processSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
positive regulation of cell population proliferationSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
response to type I interferonSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
tetrahydrofolate interconversionSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
tetrahydrofolate metabolic processSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
protein tetramerizationSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
protein homotetramerizationSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
regulation of mitochondrial translationSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
protein K63-linked deubiquitinationSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
regulation of aerobic respirationSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
glycine biosynthetic process from serineSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of protein phosphorylationVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of endothelial cell proliferationVascular endothelial growth factor receptor 3Homo sapiens (human)
vasculature developmentVascular endothelial growth factor receptor 3Homo sapiens (human)
lymph vessel developmentVascular endothelial growth factor receptor 3Homo sapiens (human)
lymphangiogenesisVascular endothelial growth factor receptor 3Homo sapiens (human)
sprouting angiogenesisVascular endothelial growth factor receptor 3Homo sapiens (human)
respiratory system processVascular endothelial growth factor receptor 3Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of cell population proliferationVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of endothelial cell migrationVascular endothelial growth factor receptor 3Homo sapiens (human)
peptidyl-tyrosine phosphorylationVascular endothelial growth factor receptor 3Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusVascular endothelial growth factor receptor 3Homo sapiens (human)
vascular endothelial growth factor signaling pathwayVascular endothelial growth factor receptor 3Homo sapiens (human)
negative regulation of apoptotic processVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of MAPK cascadeVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of JNK cascadeVascular endothelial growth factor receptor 3Homo sapiens (human)
protein autophosphorylationVascular endothelial growth factor receptor 3Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayVascular endothelial growth factor receptor 3Homo sapiens (human)
lung alveolus developmentVascular endothelial growth factor receptor 3Homo sapiens (human)
blood vessel morphogenesisVascular endothelial growth factor receptor 3Homo sapiens (human)
regulation of blood vessel remodelingVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of protein kinase C signalingVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of cell migrationVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of kinase activityVascular endothelial growth factor receptor 3Homo sapiens (human)
multicellular organism developmentVascular endothelial growth factor receptor 3Homo sapiens (human)
regulation of MAPK cascadeVascular endothelial growth factor receptor 3Homo sapiens (human)
angiogenesisVascular endothelial growth factor receptor 3Homo sapiens (human)
branching involved in blood vessel morphogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of macroautophagyVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of mitochondrial depolarizationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of mitochondrial fissionVascular endothelial growth factor receptor 2Homo sapiens (human)
angiogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
ovarian follicle developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
vasculogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of protein phosphorylationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of endothelial cell proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
lymph vessel developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
cell migration involved in sprouting angiogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of mesenchymal cell proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
epithelial cell maturationVascular endothelial growth factor receptor 2Homo sapiens (human)
endocardium developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
endothelium developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of cell population proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
regulation of cell shapeVascular endothelial growth factor receptor 2Homo sapiens (human)
mesenchymal cell proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of endothelial cell migrationVascular endothelial growth factor receptor 2Homo sapiens (human)
negative regulation of gene expressionVascular endothelial growth factor receptor 2Homo sapiens (human)
peptidyl-tyrosine phosphorylationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of cell migrationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of BMP signaling pathwayVascular endothelial growth factor receptor 2Homo sapiens (human)
embryonic hemopoiesisVascular endothelial growth factor receptor 2Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusVascular endothelial growth factor receptor 2Homo sapiens (human)
vascular endothelial growth factor receptor-2 signaling pathwayVascular endothelial growth factor receptor 2Homo sapiens (human)
peptidyl-tyrosine autophosphorylationVascular endothelial growth factor receptor 2Homo sapiens (human)
vascular endothelial growth factor signaling pathwayVascular endothelial growth factor receptor 2Homo sapiens (human)
surfactant homeostasisVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of MAPK cascadeVascular endothelial growth factor receptor 2Homo sapiens (human)
negative regulation of neuron apoptotic processVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationVascular endothelial growth factor receptor 2Homo sapiens (human)
cell fate commitmentVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of angiogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
protein autophosphorylationVascular endothelial growth factor receptor 2Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayVascular endothelial growth factor receptor 2Homo sapiens (human)
lung alveolus developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
post-embryonic camera-type eye morphogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
epithelial cell proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of positive chemotaxisVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic processVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of focal adhesion assemblyVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionVascular endothelial growth factor receptor 2Homo sapiens (human)
calcium ion homeostasisVascular endothelial growth factor receptor 2Homo sapiens (human)
blood vessel endothelial cell differentiationVascular endothelial growth factor receptor 2Homo sapiens (human)
vascular wound healingVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeVascular endothelial growth factor receptor 2Homo sapiens (human)
semaphorin-plexin signaling pathwayVascular endothelial growth factor receptor 2Homo sapiens (human)
stem cell proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
regulation of hematopoietic progenitor cell differentiationVascular endothelial growth factor receptor 2Homo sapiens (human)
regulation of bone developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
cellular response to hydrogen sulfideVascular endothelial growth factor receptor 2Homo sapiens (human)
negative regulation of endothelial cell apoptotic processVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of stem cell proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of endothelial cell chemotaxisVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of vasculogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
regulation of MAPK cascadeVascular endothelial growth factor receptor 2Homo sapiens (human)
multicellular organism developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
cell migrationVascular endothelial growth factor receptor 2Homo sapiens (human)
endothelial cell differentiationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of kinase activityVascular endothelial growth factor receptor 2Homo sapiens (human)
regulation of smooth muscle cell apoptotic processCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
cGMP catabolic processCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
regulation of smooth muscle cell proliferationCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
cAMP-mediated signalingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to hypoxiaDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
neutrophil mediated immunityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
germinal center formationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of leukocyte chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane protein ectodomain proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch receptor processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell population proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to xenobiotic stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of T cell chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
signal releaseDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
B cell differentiationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell growthDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to lipopolysaccharideDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of chemokine productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
regulation of mast cell apoptotic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
T cell differentiation in thymusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesion mediated by integrinDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
wound healing, spreading of epidermal cellsDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor-activated receptor activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
spleen developmentDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell motilityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
defense response to Gram-positive bacteriumDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cellular response to high density lipoprotein particle stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
commissural neuron axon guidanceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of cold-induced thermogenesisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to amphetamineCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
locomotory behaviorCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
visual learningCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
monocyte differentiationCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
cellular response to macrophage colony-stimulating factor stimulusCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
dopamine catabolic processCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
serotonin metabolic processCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
cellular response to granulocyte macrophage colony-stimulating factor stimulusCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
cAMP-mediated signalingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
regulation of heart ratecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cAMP catabolic processcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of heart ratecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulumcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of type II interferon productioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of interleukin-2 productioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of interleukin-5 productioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of peptidyl-serine phosphorylationcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of heart contractioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
T cell receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
establishment of endothelial barriercAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
adrenergic receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of cardiac muscle cell contractioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of cell communication by electrical coupling involved in cardiac conductioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of relaxation of cardiac musclecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channelcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cAMP-mediated signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
angiogenesiscGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
negative regulation of cell adhesioncGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
G protein-coupled receptor signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
negative regulation of angiogenesiscGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
cellular response to insulin stimuluscGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
negative regulation of cell adhesion mediated by integrincGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
negative regulation of lipid catabolic processcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
cAMP-mediated signalingcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
cAMP-mediated signalingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
oocyte maturationcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
lipid metabolic processcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
G protein-coupled receptor signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
response to xenobiotic stimuluscGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cAMP-mediated signalingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cGMP-mediated signalingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
regulation of meiotic nuclear divisioncGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
negative regulation of apoptotic processcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
negative regulation of vascular permeabilitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
positive regulation of vascular permeabilitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
steroid hormone mediated signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
negative regulation of cAMP-mediated signalingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
positive regulation of oocyte developmentcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
regulation of ribonuclease activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cellular response to cGMPcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cellular response to transforming growth factor beta stimuluscGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
apoptotic signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
negative regulation of transcription by RNA polymerase IICREB-binding proteinHomo sapiens (human)
response to hypoxiaCREB-binding proteinHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayCREB-binding proteinHomo sapiens (human)
chromatin remodelingCREB-binding proteinHomo sapiens (human)
regulation of DNA-templated transcriptionCREB-binding proteinHomo sapiens (human)
protein acetylationCREB-binding proteinHomo sapiens (human)
signal transductionCREB-binding proteinHomo sapiens (human)
canonical NF-kappaB signal transductionCREB-binding proteinHomo sapiens (human)
regulation of smoothened signaling pathwayCREB-binding proteinHomo sapiens (human)
negative regulation of transcription by RNA polymerase ICREB-binding proteinHomo sapiens (human)
N-terminal peptidyl-lysine acetylationCREB-binding proteinHomo sapiens (human)
positive regulation of transforming growth factor beta receptor signaling pathwayCREB-binding proteinHomo sapiens (human)
protein destabilizationCREB-binding proteinHomo sapiens (human)
cellular response to nutrient levelsCREB-binding proteinHomo sapiens (human)
cellular response to UVCREB-binding proteinHomo sapiens (human)
homeostatic processCREB-binding proteinHomo sapiens (human)
embryonic digit morphogenesisCREB-binding proteinHomo sapiens (human)
positive regulation of DNA-templated transcriptionCREB-binding proteinHomo sapiens (human)
positive regulation of transcription by RNA polymerase IICREB-binding proteinHomo sapiens (human)
rhythmic processCREB-binding proteinHomo sapiens (human)
protein-containing complex assemblyCREB-binding proteinHomo sapiens (human)
regulation of cellular response to heatCREB-binding proteinHomo sapiens (human)
positive regulation of protein localization to nucleusCREB-binding proteinHomo sapiens (human)
positive regulation of double-strand break repair via homologous recombinationCREB-binding proteinHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cAMP catabolic processcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AHomo sapiens (human)
cGMP catabolic processcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AHomo sapiens (human)
negative regulation of cGMP-mediated signalingcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AHomo sapiens (human)
cAMP-mediated signalingcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (130)

Processvia Protein(s)Taxonomy
magnesium ion bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP-stimulated cyclic-nucleotide phosphodiesterase activitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
protein bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
zinc ion bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cAMP bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
TPR domain bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
phosphate ion bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
protein homodimerization activitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activityHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
kinase bindingHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
protein kinase activator activityHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
metal ion bindingHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activityHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activitycGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
protein bindingcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP bindingcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
metal ion bindingcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityVascular endothelial growth factor receptor 1 Homo sapiens (human)
vascular endothelial growth factor receptor activityVascular endothelial growth factor receptor 1 Homo sapiens (human)
protein bindingVascular endothelial growth factor receptor 1 Homo sapiens (human)
ATP bindingVascular endothelial growth factor receptor 1 Homo sapiens (human)
growth factor bindingVascular endothelial growth factor receptor 1 Homo sapiens (human)
placental growth factor receptor activityVascular endothelial growth factor receptor 1 Homo sapiens (human)
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
protein bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cAMP bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
metal ion bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
iron ion bindingCytochrome P450 2C19Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxygen bindingCytochrome P450 2C19Homo sapiens (human)
enzyme bindingCytochrome P450 2C19Homo sapiens (human)
heme bindingCytochrome P450 2C19Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
aromatase activityCytochrome P450 2C19Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C19Homo sapiens (human)
chromatin bindingSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
glycine hydroxymethyltransferase activitySerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
protein bindingSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
L-allo-threonine aldolase activitySerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
amino acid bindingSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
pyridoxal phosphate bindingSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
identical protein bindingSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityVascular endothelial growth factor receptor 3Homo sapiens (human)
vascular endothelial growth factor receptor activityVascular endothelial growth factor receptor 3Homo sapiens (human)
protein bindingVascular endothelial growth factor receptor 3Homo sapiens (human)
ATP bindingVascular endothelial growth factor receptor 3Homo sapiens (human)
growth factor bindingVascular endothelial growth factor receptor 3Homo sapiens (human)
protein phosphatase bindingVascular endothelial growth factor receptor 3Homo sapiens (human)
protein homodimerization activityVascular endothelial growth factor receptor 3Homo sapiens (human)
protein tyrosine kinase activityVascular endothelial growth factor receptor 2Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityVascular endothelial growth factor receptor 2Homo sapiens (human)
vascular endothelial growth factor receptor activityVascular endothelial growth factor receptor 2Homo sapiens (human)
integrin bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
protein bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
ATP bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
coreceptor activityVascular endothelial growth factor receptor 2Homo sapiens (human)
growth factor bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
vascular endothelial growth factor bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
identical protein bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
cadherin bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
Hsp90 protein bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
calmodulin-activated dual specificity 3',5'-cyclic-GMP, 3',5'-cyclic-AMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
metal ion bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
endopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
interleukin-6 receptor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
integrin bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
peptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metallopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
SH3 domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytokine bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
PDZ domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
tumor necrosis factor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metal ion bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activity involved in amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
calmodulin-activated dual specificity 3',5'-cyclic-GMP, 3',5'-cyclic-AMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
protein bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
metal ion bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
calcium channel regulator activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
protein bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
enzyme bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
signaling receptor regulator activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cAMP bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
beta-2 adrenergic receptor bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
transmembrane transporter bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
metal ion bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
ATPase bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
scaffold protein bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
heterocyclic compound bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
cGMP-inhibited cyclic-nucleotide phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
protein bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
protein kinase B bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
metal ion bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
calmodulin-activated dual specificity 3',5'-cyclic-GMP, 3',5'-cyclic-AMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
metal ion bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cGMP-inhibited cyclic-nucleotide phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
protein bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
nuclear estrogen receptor activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
metal ion bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
estrogen bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
transcription coactivator bindingCREB-binding proteinHomo sapiens (human)
p53 bindingCREB-binding proteinHomo sapiens (human)
chromatin bindingCREB-binding proteinHomo sapiens (human)
damaged DNA bindingCREB-binding proteinHomo sapiens (human)
transcription coactivator activityCREB-binding proteinHomo sapiens (human)
transcription corepressor activityCREB-binding proteinHomo sapiens (human)
histone acetyltransferase activityCREB-binding proteinHomo sapiens (human)
protein bindingCREB-binding proteinHomo sapiens (human)
zinc ion bindingCREB-binding proteinHomo sapiens (human)
acetyltransferase activityCREB-binding proteinHomo sapiens (human)
peptide N-acetyltransferase activityCREB-binding proteinHomo sapiens (human)
MRF bindingCREB-binding proteinHomo sapiens (human)
histone H3K18 acetyltransferase activityCREB-binding proteinHomo sapiens (human)
histone H3K27 acetyltransferase activityCREB-binding proteinHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCREB-binding proteinHomo sapiens (human)
peptide-lysine-N-acetyltransferase activityCREB-binding proteinHomo sapiens (human)
peptide lactyltransferase activityCREB-binding proteinHomo sapiens (human)
DNA-binding transcription factor bindingCREB-binding proteinHomo sapiens (human)
chromatin DNA bindingCREB-binding proteinHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activitycAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AHomo sapiens (human)
cGMP-stimulated cyclic-nucleotide phosphodiesterase activitycAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AHomo sapiens (human)
cAMP bindingcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AHomo sapiens (human)
cGMP bindingcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AHomo sapiens (human)
metal ion bindingcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (66)

Processvia Protein(s)Taxonomy
plasma membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
nucleuscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cytoplasmcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
mitochondrial outer membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
mitochondrial inner membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
endoplasmic reticulumcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
Golgi apparatuscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cytosolcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
plasma membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
presynaptic membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
perinuclear region of cytoplasmcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
nucleuscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
mitochondrial inner membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
perinuclear region of cytoplasmcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
mitochondrial outer membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
synaptic membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cytosolcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
mitochondrial matrixcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
cytosolHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
extracellular exosomeHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
perinuclear region of cytoplasmHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
cytosolHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
nucleusHigh affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)
cellular_componentcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cytosolcGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
extracellular spaceVascular endothelial growth factor receptor 1 Homo sapiens (human)
endosomeVascular endothelial growth factor receptor 1 Homo sapiens (human)
plasma membraneVascular endothelial growth factor receptor 1 Homo sapiens (human)
focal adhesionVascular endothelial growth factor receptor 1 Homo sapiens (human)
actin cytoskeletonVascular endothelial growth factor receptor 1 Homo sapiens (human)
receptor complexVascular endothelial growth factor receptor 1 Homo sapiens (human)
plasma membraneVascular endothelial growth factor receptor 1 Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
nucleoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
plasma membranecAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
membranecAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
ruffle membranecAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
nucleuscAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C19Homo sapiens (human)
plasma membraneCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
cytoplasmCytochrome P450 2C19Homo sapiens (human)
nucleusSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
cytoplasmSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
mitochondrionSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
mitochondrial inner membraneSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
mitochondrial matrixSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
microtubule cytoskeletonSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
mitochondrial nucleoidSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
extracellular exosomeSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
BRISC complexSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
mitochondrionSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
cytoplasmSerine hydroxymethyltransferase, mitochondrialHomo sapiens (human)
extracellular regionVascular endothelial growth factor receptor 3Homo sapiens (human)
nucleoplasmVascular endothelial growth factor receptor 3Homo sapiens (human)
cytosolVascular endothelial growth factor receptor 3Homo sapiens (human)
plasma membraneVascular endothelial growth factor receptor 3Homo sapiens (human)
receptor complexVascular endothelial growth factor receptor 3Homo sapiens (human)
plasma membraneVascular endothelial growth factor receptor 3Homo sapiens (human)
extracellular regionVascular endothelial growth factor receptor 2Homo sapiens (human)
nucleusVascular endothelial growth factor receptor 2Homo sapiens (human)
endosomeVascular endothelial growth factor receptor 2Homo sapiens (human)
early endosomeVascular endothelial growth factor receptor 2Homo sapiens (human)
endoplasmic reticulumVascular endothelial growth factor receptor 2Homo sapiens (human)
Golgi apparatusVascular endothelial growth factor receptor 2Homo sapiens (human)
plasma membraneVascular endothelial growth factor receptor 2Homo sapiens (human)
external side of plasma membraneVascular endothelial growth factor receptor 2Homo sapiens (human)
cell junctionVascular endothelial growth factor receptor 2Homo sapiens (human)
membrane raftVascular endothelial growth factor receptor 2Homo sapiens (human)
anchoring junctionVascular endothelial growth factor receptor 2Homo sapiens (human)
sorting endosomeVascular endothelial growth factor receptor 2Homo sapiens (human)
plasma membraneVascular endothelial growth factor receptor 2Homo sapiens (human)
receptor complexVascular endothelial growth factor receptor 2Homo sapiens (human)
cytosolCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
neuronal cell bodyCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
cell-cell junctionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
focal adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
ruffle membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Golgi membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytoplasmDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
endoplasmic reticulum lumenDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytosolDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell surfaceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
actin cytoskeletonDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
apical plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane raftDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytosolCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
neuronal cell bodyCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
centrosomecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
plasma membranecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
apical plasma membranecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
voltage-gated calcium channel complexcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
calcium channel complexcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
nucleuscAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
endoplasmic reticulumcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
Golgi apparatuscGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
cytosolcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
membranecGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
guanyl-nucleotide exchange factor complexcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
lysosomeCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
cytosolCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
neuronal cell bodyCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
cytosolcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
membranecGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cytosolcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cytoplasmCREB-binding proteinHomo sapiens (human)
nucleusCREB-binding proteinHomo sapiens (human)
nucleoplasmCREB-binding proteinHomo sapiens (human)
cytoplasmCREB-binding proteinHomo sapiens (human)
cytosolCREB-binding proteinHomo sapiens (human)
nuclear bodyCREB-binding proteinHomo sapiens (human)
chromatinCREB-binding proteinHomo sapiens (human)
histone acetyltransferase complexCREB-binding proteinHomo sapiens (human)
transcription regulator complexCREB-binding proteinHomo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cytosolcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (227)

Assay IDTitleYearJournalArticle
AID1799753Enzymatic Assay from Article 10.1074/jbc.M111.326777: \\Biological and structural characterization of Trypanosoma cruzi phosphodiesterase C and Implications for design of parasite selective inhibitors.\\2012The Journal of biological chemistry, Apr-06, Volume: 287, Issue:15
Biological and structural characterization of Trypanosoma cruzi phosphodiesterase C and Implications for design of parasite selective inhibitors.
AID1797286PDE Competitive Enzyme Inhibition Assay from Article 10.1021/jm060653b: \\Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.\\2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID158892Inhibition of [Ca(2+)]/calmodulin dependent phosphodiesterase PDE 1 of human lung1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.
AID1625381Inhibition of PDE4D (unknown origin)2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.
AID1876242Antiviral activity against PIV52022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Kinase Inhibitors as Underexplored Antiviral Agents.
AID628752Inhibition of bovine aortic PDE4 using cAMP as substrate in presence of cGMP2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
New PDE4 inhibitors based on pharmacophoric similarity between papaverine and tofisopam.
AID380881Inhibition of rat ileum contraction1999Journal of natural products, Aug, Volume: 62, Issue:8
New phenanthrene derivatives from maxillaria densa(1)
AID269392Potency index, spasmolytic activity in Wistar rat ileum relative to gigantol2006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
Design, microwave-assisted synthesis, and spasmolytic activity of 2-(alkyloxyaryl)-1H-benzimidazole derivatives as constrained stilbene bioisosteres.
AID193699Percent change in systolic blood pressure (mmHg)in anesthetized rats by i.v. administration1999Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22
Further hypotensive metabolites from Verbesina caracasana.
AID332780Anticholinergic effect in guinea pig ileum assessed as inhibition of acetylcholine-induced contraction
AID615722Selectivity ratio of IC50 for rat PDE10A to IC50 for rat PDE3A2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis and in vitro evaluation of new analogues as inhibitors for phosphodiesterase 10A.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID197290Changes in diastolic Blood pressure following iv administration at (5 umol/kg) anesthetized rats2001Journal of medicinal chemistry, Aug-30, Volume: 44, Issue:18
Novel hypotensive agents from Verbesina caracasana. 8. Synthesis and pharmacology of (3,4-dimethoxycinnamoyl)-N(1)-agmatine and synthetic analogues.
AID1134344Toxicity in Swiss albino mouse assessed as loss of righting reflex at 100 mg/kg, sc measured up to 20 mins1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Isoquinolines. 5. Synthesis and antiarrhythmic activity of benzylisoquinoline derivatives.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID400000Antiplatelet activity in Sprague-Dawley rat platelet-rich plasma assessed as minimum drug level causing inhibition of collagen-induced platelet aggregation administered 2 mins before collagen challenge by modified smear method
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1876241Antiviral activity against Influenza B virus B/MD/592022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Kinase Inhibitors as Underexplored Antiviral Agents.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1640018Luciferase/luciferin-expressing antifolate-resistant parasites were used to infect a culture of HepG2 cells that were pre-incubated with compounds. Infected hepatocytes emit light due to the luciferase reaction. Assay results are presented as the percent 2018Science (New York, N.Y.), 12-07, Volume: 362, Issue:6419
Open-source discovery of chemical leads for next-generation chemoprotective antimalarials.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID399998Antiplatelet activity in Sprague-Dawley rat platelet-rich plasma assessed as minimum drug level causing inhibition of arachidonic acid-induced platelet aggregation administered 2 mins before arachidonic acid challenge by modified smear method
AID1640019Luciferase/luciferin-expressing antifolate-resistant parasites were used to infect a culture of HepG2 cells that were pre-incubated with compounds. Infected hepatocytes emit light due to the luciferase reaction. Assay results are presented as the percent 2018Science (New York, N.Y.), 12-07, Volume: 362, Issue:6419
Open-source discovery of chemical leads for next-generation chemoprotective antimalarials.
AID397122Inhibition of HIV1 RT
AID550507Inhibition of human PDE10A expressed in Sf9 cells using [3H]cAMP by scintillation proximity assay2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Synthesis and SAR study of new phenylimidazole-pyrazolo[1,5-c]quinazolines as potent phosphodiesterase 10A inhibitors.
AID171824Change in systolic blood pressure after iv administration of 5 uM/kg in anesthetized rats1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Novel hypotensive agents from Verbesina caracasana. 6. Synthesis and pharmacology of caracasandiamide.
AID1596330Inhibition of recombinant -N-terminal GST-tagged human PDE10A1 (aa 2-789) expressed in Sf9 cells using FAM-cAMP as substrate at 10xIC50 incubated for 60 mins by fluorescence plate reader analysis2019European journal of medicinal chemistry, Jul-15, Volume: 174InCl
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID180832Tested for change in heart rate administered at 5 uM/kg iv in anesthetized rats1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
Novel hypotensive agents from Verbesina caracasana. 2. Synthesis and pharmacology of caracasanamide.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID220175Inhibition of [Ca(2+)]-calmodulin-dependent cGMP-phosphodiesterase 1 from porcine coronary arteries1993Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24
Cyclic GMP phosphodiesterase inhibitors. 1. The discovery of a novel potent inhibitor, 4-((3,4-(methylenedioxy)benzyl)amino)-6,7,8-trimethoxyquinazoline.
AID263607Inhibition of AChE at 0.01 mM2006Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8
Isoquinoline derivatives as potential acetylcholinesterase inhibitors.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID311935Partition coefficient, log P of the compound2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID275399Inhibition of rat recombinant PDE10A transfected in Sf9 cells by SPA2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1876237Antiviral activity against Influenza B virus B/Lee/402022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Kinase Inhibitors as Underexplored Antiviral Agents.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID705188Inhibition of PDE3A2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Current landscape of phosphodiesterase 10A (PDE10A) inhibition.
AID767814Inhibition of PDE10A (unknown origin)2013Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19
N-Methylanilide and N-methylbenzamide derivatives as phosphodiesterase 10A (PDE10A) inhibitors.
AID1876239Antiviral activity against Influenza A virus A/Equine/2/MIAMI/1/63 (H3N8))2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Kinase Inhibitors as Underexplored Antiviral Agents.
AID615719Inhibition of human recombinant PDE10A assessed as reduction in hydrolysis of [3H]cAMP by scintillation proximity assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis and in vitro evaluation of new analogues as inhibitors for phosphodiesterase 10A.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1552312Inhibition of PDE3A (unknown origin)2019Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15
Discovery of a pyrazolo[1,5-a]pyrimidine derivative (MT-3014) as a highly selective PDE10A inhibitor via core structure transformation from the stilbene moiety.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID395325Lipophilicity, log P by microemulsion electrokinetic chromatography2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID205269Inhibition of binding of Batrachotoxinin [3H]BTX-B to high-affinity sites on voltage-dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 100 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID275400Inhibition of human recombinant PDE3A transfected in Sf9 cells by SPA2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.
AID1395054Inhibition of recombinant rat PDE10A expressed in Sf9 insect cells using cGMP or cAMP as substrate by scintillation proximity assay2018European journal of medicinal chemistry, Apr-25, Volume: 150Inhibitors of phosphodiesterase as cancer therapeutics.
AID1542676Inhibition of recombinant rat PDE10A expressed in Sf9 cells using cGMP/cAMP as substrate by scintillation proximity assay2019Bioorganic & medicinal chemistry letters, 06-01, Volume: 29, Issue:11
Benzothiophene derivatives as phosphodiesterase 10A (PDE10A) inhibitors: Hit-to-lead studies.
AID171666Change in diastolic blood pressure after iv administration of 5 uM/kg in anesthetized rats1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Novel hypotensive agents from Verbesina caracasana. 6. Synthesis and pharmacology of caracasandiamide.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1136068Vasodilatory activity in dog assessed as increase of femoral blood flow by 100 mL/min administered as intraarterially1979Journal of medicinal chemistry, Dec, Volume: 22, Issue:12
Derivatives of 1,3-disubstituted 2,4(1H,3H)-quinazolinediones as possible peripheral vasodilators or antihypertensive agents.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID55210Inhibition of Ca-dependent phosphodiesterase from Rat cerebral cortex using 1 uM cAMP1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
1-(4-Aminobenzyl)-and 1-(4-aminophenyl)isoquinoline derivatives: synthesis and evaluation as potential irreversible cyclic nucleotide phosphodiesterase inhibitors.
AID192882Maximum rate of rise of the left ventricular isovolumetric pressure was measured after iv administration of 5 uM/kg in anesthetized rats; ratio given for dP/dt1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Novel hypotensive agents from Verbesina caracasana. 6. Synthesis and pharmacology of caracasandiamide.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID55208Inhibitory activity against cyclic nucleotide phosphodiesterase in bovine heart carried out at 37 C with cAMP (1 M) as substrate.1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
1-(4-Aminobenzyl)-and 1-(4-aminophenyl)isoquinoline derivatives: synthesis and evaluation as potential irreversible cyclic nucleotide phosphodiesterase inhibitors.
AID1596307Inhibition of recombinant -N-terminal GST-tagged human PDE10A1 (aa 2-789) expressed in Sf9 cells using FAM-cAMP as substrate at 1xIC50 incubated for 60 mins by fluorescence plate reader analysis2019European journal of medicinal chemistry, Jul-15, Volume: 174InCl
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID334626Inhibition of acetylcholine-induced contraction in guinea pig ileum preincubated for 5 mins before acetylcholine challenge
AID1596309Inhibition of recombinant N-terminal GST-tagged full length human PDE10A2 expressed in Sf9 cells using FAM-cAMP as substrate at 1xIC50 incubated for 60 mins by fluorescence plate reader analysis2019European journal of medicinal chemistry, Jul-15, Volume: 174InCl
AID615723Lipophilicity, log D of the compound2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis and in vitro evaluation of new analogues as inhibitors for phosphodiesterase 10A.
AID170674Tested for the change in diastolic blood pressure administered at 5 ug/kg intravenously in anesthetized rats1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
Novel hypotensive agents from Verbesina caracasana. 2. Synthesis and pharmacology of caracasanamide.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID484805Inhibition of human recombinant PDE10A expressed in baculovirus-SF21 cell system assessed as hydrolysis of [3H]cAMP after 1 hr by liquid scintillation counting2010Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors.
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID377018Antispasmodic activity in guinea pig ileum assessed as inhibition of acetylcholine-induced contraction at 30 ug/mL2006Journal of natural products, Jun, Volume: 69, Issue:6
Spasmolytic effects of nonprenylated rotenoid constituents of Boerhaavia diffusa roots.
AID1267450Competitive inhibition of rat recombinant PDE10A by scintillation proximity assay in presence of cAMP2016Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1
Fragment-assisted hit investigation involving integrated HTS and fragment screening: Application to the identification of phosphodiesterase 10A (PDE10A) inhibitors.
AID1876236Antiviral activity against Influenza A virus (A/WSN/33 (H1N1))2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Kinase Inhibitors as Underexplored Antiviral Agents.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1743696Inhibition of PDE10A (unknown origin)2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Why All the Fuss about Oxidative Phosphorylation (OXPHOS)?
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID615720Inhibition of PDE3A assessed as reduction in hydrolysis of [3H]cAMP by scintillation proximity assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis and in vitro evaluation of new analogues as inhibitors for phosphodiesterase 10A.
AID1542658Inhibition of human MOLT4 cell-derived PDE10A using [3H]cAMP as substrate measured after 2 hrs in presence of rolipram/milrinone by topcount method2019Bioorganic & medicinal chemistry letters, 06-01, Volume: 29, Issue:11
Benzothiophene derivatives as phosphodiesterase 10A (PDE10A) inhibitors: Hit-to-lead studies.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID220176Inhibitory activity against cyclic GMP-phosphodiesterase (PDE V) isolated from porcine aorta.1993Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24
Cyclic GMP phosphodiesterase inhibitors. 1. The discovery of a novel potent inhibitor, 4-((3,4-(methylenedioxy)benzyl)amino)-6,7,8-trimethoxyquinazoline.
AID55334Inhibition of Ca-dependent phosphodiesterase from Rat cerebral cortex using 1 uM cGMP1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
1-(4-Aminobenzyl)-and 1-(4-aminophenyl)isoquinoline derivatives: synthesis and evaluation as potential irreversible cyclic nucleotide phosphodiesterase inhibitors.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID650201Inhibition of human recombinant full length PDE10A using cAMP as substrate preincubated for 20 mins measured after 4 hrs2012Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
Discovery of 4-hydroxy-1,6-naphthyridine-3-carbonitrile derivatives as novel PDE10A inhibitors.
AID269391Spasmolytic activity in Wistar rat ileum2006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
Design, microwave-assisted synthesis, and spasmolytic activity of 2-(alkyloxyaryl)-1H-benzimidazole derivatives as constrained stilbene bioisosteres.
AID1727165Inhibition of human recombinant PDE10A using cAMP as substrate incubated for 20 mins measured by Kinase Glo reagent based microplate reader assay2021European journal of medicinal chemistry, Jan-01, Volume: 209New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases.
AID192927Maximum rate of rise of the left ventricular isovolumetric pressure administered at 5 uM/kg iv in anesthetized rats1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
Novel hypotensive agents from Verbesina caracasana. 2. Synthesis and pharmacology of caracasanamide.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID205268Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID615725Selectivity ratio of IC50 for rat PDE10A to IC50 for rat PDE3B2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis and in vitro evaluation of new analogues as inhibitors for phosphodiesterase 10A.
AID1134343Toxicity in Swiss albino mouse assessed as convulsions at 100 mg/kg, sc measured up to 20 mins1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Isoquinolines. 5. Synthesis and antiarrhythmic activity of benzylisoquinoline derivatives.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1370499Inhibition of oxytocin-induced uterus contraction in non-pregnant Sprague-Dawley rat measured for 300 secs2018Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3
Effects of newly synthetized isoquinoline derivatives on rat uterine contractility and ROCK II activity.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID170843Tested for the change in systolic blood pressure administered at 5 ug/kg intravenously in anesthetized rats1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
Novel hypotensive agents from Verbesina caracasana. 2. Synthesis and pharmacology of caracasanamide.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1557504Inhibition of PDE3A (unknown origin)2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Validation of Phosphodiesterase-10 as a Novel Target for Pulmonary Arterial Hypertension via Highly Selective and Subnanomolar Inhibitors.
AID399999Antiplatelet activity in Sprague-Dawley rat platelet-rich plasma assessed as minimum drug level causing inhibition of ADP-induced platelet aggregation administered 2 mins before ADP challenge by modified smear method
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID193680Maximum rate of rise of the left ventricular isovolumetric pressure (dP/dt, an index of cardiac inotropism in mmHg/sec)in anesthetized rats by i.v. administration1999Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22
Further hypotensive metabolites from Verbesina caracasana.
AID158594Inhibition of cGMP-inhibited phosphodiesterase from porcine coronary arteries1993Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24
Cyclic GMP phosphodiesterase inhibitors. 1. The discovery of a novel potent inhibitor, 4-((3,4-(methylenedioxy)benzyl)amino)-6,7,8-trimethoxyquinazoline.
AID311934Dissociation constant, pKa of the compound2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID193687Percent change in diastolic blood pressure (mmHg)in anesthetized rats by i.v. administration1999Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22
Further hypotensive metabolites from Verbesina caracasana.
AID1876240Antiviral activity against Influenza A virus (A/PR/8/34 (H1N1))2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Kinase Inhibitors as Underexplored Antiviral Agents.
AID1596285Inhibition of recombinant -N-terminal GST-tagged human PDE10A1 (aa 2-789) expressed in Sf9 cells using FAM-cAMP as substrate at 0.1xIC50 incubated for 60 mins by fluorescence plate reader analysis2019European journal of medicinal chemistry, Jul-15, Volume: 174InCl
AID1768729Lipophilicity, logP of compound by shake flask method2021Bioorganic & medicinal chemistry letters, 10-01, Volume: 49Estimation of the lipophilicity of purine-2,6-dione-based TRPA1 antagonists and PDE4/7 inhibitors with analgesic activity.
AID275401Inhibition of human recombinant PDE3B transfected in Sf9 cells by SPA2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1876238Antiviral activity against Influenza A virus (A/Udorn/72 (H3N2))2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Kinase Inhibitors as Underexplored Antiviral Agents.
AID158293Inhibition of cyclic GMP sensitive phosphodiesterase PDE 2 of human lung1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.
AID158598Inhibition of cGMP-stimulated phosphodiesterase 2 of porcine coronary arteries1993Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24
Cyclic GMP phosphodiesterase inhibitors. 1. The discovery of a novel potent inhibitor, 4-((3,4-(methylenedioxy)benzyl)amino)-6,7,8-trimethoxyquinazoline.
AID515780Intrinsic solubility of the compound in water2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
QSAR-based solubility model for drug-like compounds.
AID705199Inhibition of PDE10A2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Current landscape of phosphodiesterase 10A (PDE10A) inhibition.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID158305Inhibition of low Km cAMP phosphodiesterase PDE III of human lung1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.
AID399545Spasmolytic activity in guinea pig ileum assessed as inhibition of spontaneous contraction2004Journal of natural products, Feb, Volume: 67, Issue:2
Spasmolytic effects, mode of action, and structure-activity relationships of stilbenoids from Nidema boothii.
AID1140225Inhibition of PDE10A (unknown origin)2014Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9
Radiosyntheses and in vivo evaluation of carbon-11 PET tracers for PDE10A in the brain of rodent and nonhuman primate.
AID311932Inhibition of ASM in human H4 cells assessed as residual activity at 10 uM2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1134345Toxicity in Swiss albino mouse assessed as mortality at 100 mg/kg, sc measured up to 20 mins1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Isoquinolines. 5. Synthesis and antiarrhythmic activity of benzylisoquinoline derivatives.
AID1768730Relative lipophilicity of the compound in methanol assessed as retardation factor by reversed-phase TLC analysis2021Bioorganic & medicinal chemistry letters, 10-01, Volume: 49Estimation of the lipophilicity of purine-2,6-dione-based TRPA1 antagonists and PDE4/7 inhibitors with analgesic activity.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID403109Inhibition of PDE in Sprague-Dawley rat epididymal adipose tissue assessed as [14C]adenosine recovery at 100 uM by liquid scintillation counting1998Journal of natural products, Nov, Volume: 61, Issue:11
Inhibition of cAMP-phosphodiesterase by biflavones of Ginkgo biloba in rat adipose tissue.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID615721Inhibition of PDE3B assessed as reduction in hydrolysis of [3H]cAMP by scintillation proximity assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis and in vitro evaluation of new analogues as inhibitors for phosphodiesterase 10A.
AID395328Lipophilicity, log P of the compound2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID332781Anticholinergic effect in rat intestine assessed as inhibition of acetylcholine-induced contraction
AID1190578Binding affinity to PDE10A (unknown origin)2015Bioorganic & medicinal chemistry letters, Feb-15, Volume: 25, Issue:4
Synthesis and in vitro characterization of cinnoline and benzimidazole analogues as phosphodiesterase 10A inhibitors.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID219692Inhibition of human platelet cAMP Phosphodiesterase1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
7-(Ethoxycarbonyl)-6,8-dimethyl-2-phenyl-1(2H)-phthalazinone derivatives: synthesis and inhibitory effects on platelet aggregation.
AID1596286Inhibition of recombinant N-terminal GST-tagged full length human PDE10A2 expressed in Sf9 cells using FAM-cAMP as substrate at 0.1xIC50 incubated for 60 mins by fluorescence plate reader analysis2019European journal of medicinal chemistry, Jul-15, Volume: 174InCl
AID263606Inhibition of AChE at 0.1 mM2006Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8
Isoquinoline derivatives as potential acetylcholinesterase inhibitors.
AID1596331Inhibition of recombinant N-terminal GST-tagged full length human PDE10A2 expressed in Sf9 cells using FAM-cAMP as substrate at 10xIC50 incubated for 60 mins by fluorescence plate reader analysis2019European journal of medicinal chemistry, Jul-15, Volume: 174InCl
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1124818Activation of FXR (unknown origin) at 10 uM2014Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7
Some non-conventional biomolecular targets for diamidines. A short survey.
AID158450Inhibition of rat lung cAMP-phosphodiesterase1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Substituted 6,7-dihydroimidazo[1,2-a]purin-9(4H)-ones.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID193688Percent change in heart rate expressed in beats / min in anesthetized rats by i.v. administration1999Bioorganic & medicinal chemistry letters, Nov-15, Volume: 9, Issue:22
Further hypotensive metabolites from Verbesina caracasana.
AID180798Change in heart rate after iv administration of 5 uM/kg in anesthetized rats1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Novel hypotensive agents from Verbesina caracasana. 6. Synthesis and pharmacology of caracasandiamide.
AID598564Inhibition of PDE10A2011Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
Triazoloquinazolines as a novel class of phosphodiesterase 10A (PDE10A) inhibitors.
AID158589Inhibition of cAMP specific phosphodiesterase from porcine coronary arteries1993Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24
Cyclic GMP phosphodiesterase inhibitors. 1. The discovery of a novel potent inhibitor, 4-((3,4-(methylenedioxy)benzyl)amino)-6,7,8-trimethoxyquinazoline.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1552311Inhibition of PDE10A (unknown origin)2019Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15
Discovery of a pyrazolo[1,5-a]pyrimidine derivative (MT-3014) as a highly selective PDE10A inhibitor via core structure transformation from the stilbene moiety.
AID1743695Inhibition of mitochondrial complex 1 in human A549 cells assessed as oxygen consumption rate by seahorse analysis2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Why All the Fuss about Oxidative Phosphorylation (OXPHOS)?
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID576612Inhibition of human ERG2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
AID615724Inhibition of rat PDE10A2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis and in vitro evaluation of new analogues as inhibitors for phosphodiesterase 10A.
AID263610Inhibition of AChE activity2006Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8
Isoquinoline derivatives as potential acetylcholinesterase inhibitors.
AID1557505Inhibition of PDE4A (unknown origin)2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Validation of Phosphodiesterase-10 as a Novel Target for Pulmonary Arterial Hypertension via Highly Selective and Subnanomolar Inhibitors.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID197299Changes in systolic Blood pressure following iv administration at (5 umol/kg) anesthetized rats2001Journal of medicinal chemistry, Aug-30, Volume: 44, Issue:18
Novel hypotensive agents from Verbesina caracasana. 8. Synthesis and pharmacology of (3,4-dimethoxycinnamoyl)-N(1)-agmatine and synthetic analogues.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347087qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Confirmatory Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347084qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Confirmatory Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347081qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Confirmatory Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347088qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): Viability assay - Alamar blue signal for LCMV Confirmatory Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2010Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID493017Wombat Data for BeliefDocking1993Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24
Cyclic GMP phosphodiesterase inhibitors. 1. The discovery of a novel potent inhibitor, 4-((3,4-(methylenedioxy)benzyl)amino)-6,7,8-trimethoxyquinazoline.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5,473)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903444 (62.93)18.7374
1990's1103 (20.15)18.2507
2000's532 (9.72)29.6817
2010's303 (5.54)24.3611
2020's91 (1.66)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 82.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index82.14 (24.57)
Research Supply Index8.75 (2.92)
Research Growth Index4.23 (4.65)
Search Engine Demand Index152.24 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (82.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials305 (5.06%)5.53%
Reviews222 (3.68%)6.00%
Case Studies204 (3.38%)4.05%
Observational5 (0.08%)0.25%
Other5,291 (87.79%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (14)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Treatment of Prostatic Hyperplasia With Topical Papaverine [NCT03064282]Early Phase 140 participants (Anticipated)Interventional2021-06-30Not yet recruiting
Optimal Analgesia in Acute Gastroenteritis in Emergency Department Setting: Dipyrone Versus Papaverine [NCT02711241]Phase 315 participants (Actual)Interventional2010-06-30Terminated(stopped due to Not enough patients)
An Open Study Comparing the Effects of Moxaverine on Ocular Blood Flow in Patients With Age- Related Macular Degeneration, Primary Open Angle Glaucoma and Healthy Control Subjects [NCT00709449]Phase 2/Phase 360 participants (Anticipated)Interventional2008-05-31Completed
A Phase I Trial Combining Papaverine and Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer or Lung Metastases [NCT03824327]Phase 124 participants (Anticipated)Interventional2019-02-07Suspended(stopped due to Per an amendment)
A Phase I Trial Targeting Mitochondrial Metabolism With Papaverine in Combination With Chemoradiation for Stage II-III Non-Small Cell Lung Cancer [NCT05136846]Phase 128 participants (Anticipated)Interventional2021-12-06Recruiting
The Effect of Periradial Injection of Papaverine Versus Nitroglycerine on Radial Artery Diameter Prior to Cannulation. [NCT04030663]Early Phase 190 participants (Actual)Interventional2019-02-05Completed
Effect of Papaverine on Intraoperative Renal Artery Blood Flow Volume in Patients Undergoing Robot-assisted Partial Nephrectomy : a Randomized, Placebo-controlled Study [NCT04162834]Phase 496 participants (Actual)Interventional2019-11-21Completed
Comparison of the Efficacy and Tolerability of Drotaverine 80 mg, Ibuprofen 400 mg and Their Combination in a Calendar Packaging for the Treatment of Primary and Secondary Dysmenorrhoea [NCT00292747]Phase 4480 participants Interventional2005-05-25Terminated(stopped due to early termination due to loss of interest and low enrollment of patient)
A Multicenter regIstry on the Diagnosis of Patients With Chronic Angina and no Angiographic coRonary Artery Stenosis (International Retrospective Collection of Anonymized Patient Data) - Searching a New Ach Spasm Definition [NCT06125392]1,000 participants (Anticipated)Observational [Patient Registry]2023-09-30Recruiting
A Randomized Phase II Trial Evaluating the Importance of Early Erectile Dysfunction Rehabilitation and Unilateral Autologous Sural Nerve Sparing Radical Prostatectomy Clinically Localized Prostate Cancer [NCT00080808]Phase 2111 participants (Actual)Interventional2001-08-31Completed
Double-Blind, Randomized, Controlled Trial, Small Volume Bolus of Papaverine Versus Heparin to Maintain Patency of Peripheral Arterial Catheters in Pediatric Patients Undergoing Surgical Procedures: Pilot Study [NCT03894904]Phase 4100 participants (Actual)Interventional2019-04-01Completed
PDE Inhibitors Effect on Cognitive Deficits Associated to Schizophrenia [NCT01813955]Early Phase 15 participants (Actual)Interventional2011-06-30Terminated(stopped due to Patient recruitment insufficient)
The Effect of IV PAPAVERINE 80 mg Prior to Catheter Balloon Insertion on Bishop Score and Pain, Double Blinded Randomized Placebo Controlled Trial [NCT05759364]128 participants (Anticipated)Interventional2023-05-15Recruiting
The Efficacy of Papaverine to Prevent Radial Artery Spasm During Transradial Cerebral Angiography: A Randomized Controlled Trial [NCT05861765]Phase 2240 participants (Anticipated)Interventional2023-05-24Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT03894904 (3) [back to overview]Number of Participants With Optimal Arterial Waveform
NCT03894904 (3) [back to overview]Number of Participants With Optimal Arterial Waveform
NCT03894904 (3) [back to overview]Number of Participants With Suboptimal Waveforms Who Received Rescue Papaverine and for Whom Papaverine Rescued Suboptimal Waveforms

Number of Participants With Optimal Arterial Waveform

Optimal waveform was defined as easy aspiration of a blood sample (negative aspiration is easy and draws back freely without cavitation, and takes no more than 30 seconds to draw 1 mL), absence of color change at the catheter insertion site, and presence of a dicrotic notch in the arterial pressure waveform (a distinct dicrotic notch implies system has good resolution at higher frequencies and is not overdamped). (NCT03894904)
Timeframe: 5 minutes after first dose

InterventionParticipants (Count of Participants)
Papaverine Plus Heparin During Procedure, With Rescue Papaverine as Needed27
Heparin During Procedure, With Rescue Papaverine as Needed18

[back to top]

Number of Participants With Optimal Arterial Waveform

Optimal waveform was defined as easy aspiration of a blood sample (negative aspiration is easy and draws back freely without cavitation, and takes no more than 30 seconds to draw 1 mL), absence of color change at the catheter insertion site, and presence of a dicrotic notch in the arterial pressure waveform (a distinct dicrotic notch implies system has good resolution at higher frequencies and is not overdamped). (NCT03894904)
Timeframe: 60 minutes after first dose

InterventionParticipants (Count of Participants)
Papaverine Plus Heparin During Procedure, With Rescue Papaverine as Needed30
Heparin During Procedure, With Rescue Papaverine as Needed28

[back to top]

Number of Participants With Suboptimal Waveforms Who Received Rescue Papaverine and for Whom Papaverine Rescued Suboptimal Waveforms

These data were collected only from participants who received rescue papaverine. 7 in the Papaverine plus Heparin arm received rescue papaverine. 17 in the Heparin arm received rescue papaverine. (NCT03894904)
Timeframe: 5 minutes after injection of rescue papaverine (about 70 minutes after first study drug dose and about 10 minutes after second study drug dose)

InterventionParticipants (Count of Participants)
Papaverine Plus Heparin During Procedure, With Rescue Papaverine as Needed3
Heparin During Procedure, With Rescue Papaverine as Needed13

[back to top]